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ABSTRACT: The design, synthesis, and evaluation of the potency of new
isoform-selective inhibitors of sphingosine kinases 1 and 2 (SK1 and SK2),
the enzyme that catalyzes the phosphorylation of D-erythro-sphingosine to
produce the key signaling lipid, sphingosine 1-phosphate, are described.
Recently, we reported that 1-(4-octylphenethyl)piperidin-4-ol (RB-005) is a
selective inhibitor of SK1. Here we report the synthesis of 43 new analogues
of RB-005, in which the lipophilic tail, polar headgroup, and linker region
were modiﬁed to extend the structure−activity relationship proﬁle for this
lead compound, which we explain using modeling studies with the recently
published crystal structure of SK1. We provide a basis for the key residues
targeted by our proﬁled series and provide further evidence for the ability to
discriminate between the two isoforms using pharmacological intervention.
■ INTRODUCTION
The lipid kinase, sphingosine kinase (SK), plays a myriad of roles
in regulating cell survival, growth, and migration of mammalian
cells through its product, sphingosine 1-phosphate (S1P). S1P is
a ligand for ﬁve cell-surface G-protein-coupled receptors and for
several intracellular targets, such as histone deacetylases 1 and 2
(HDAC1/2, which regulate gene expression).1 There are two
isoforms of sphingosine kinase, SK1 and SK2, that are encoded
by diﬀerent genes and that exhibit distinct biochemical
properties, substrate and inhibitor sensitivities, and subcellular
distribution. SK1 and SK2 have redundant roles to some extent
as knockout of both genes is embyronically lethal in mice,
whereas animals survive when either gene is removed alone.2
Moreover, there is evidence that both SK1 and SK2 play a similar
role in certain cancers.3,4 Surprisingly, SK1 and SK2 may have
opposing roles in inﬂammation, being largely proinﬂammatory
and antiinﬂammatory, respectively. On the other hand, a
proinﬂammatory role for SK2 in other cell types has also been
reported.3 The diﬀering roles of SK1 and SK2 in inﬂammatory
disease and supporting data from knockout mice make a
compelling case for the development of isoform-selective
inhibitors in order to elucidate the functions and roles of each
isozyme and for designing drugs for therapeutic intervention in
pathophysiological processes such as inﬂammatory diseases and
cancer.
Various SK inhibitors have been identiﬁed (see Figure 1 for
examples). Enzyme kinetic studies show that many of these are
competitive with sphingosine (Sph). The initial SK inhibitors
were Sph analogues, such as D,L-threo-dihydrosphingosine which
has a Ki of ∼5 μM.3 N,N-Dimethylsphingosine also inhibits both
SK isoforms. The ﬁrst SK1-selective inhibitor to be reported was
the water-soluble Sph analogue SK1-I (also known as BML-258;
Ki ∼ 10 μM).5 The most potent nanomolar SK1-selective
inhibitor is PF-543.6 However, this compound is also a substrate
for SK1, thereby compromising data interpretation. Analogues of
the immunosuppressive agent FTY720 (Gilenya) have been
prepared using a synthetic route starting with 4-octylphenethyl
alcohol and were found to be SK1-selective inhibitors (e.g., RB-
005).7 FTY720 is an inhibitor of SK18 and also inhibits other
sphingolipid-metabolizing enzymes, such as ceramide synthase
and S1P lyase.9,10 We also recently showed that SK1 contains an
allosteric site.11 Replacement of the amino group in (S)-FTY720-
vinylphosphonate with an azido group changes this compound
from an allosteric inhibitor to an activator of SK1.12 Therefore,
allosteric inhibitors of SK1 are also an exciting option for future
study. With regard to SK2-selective inhibitors, ABC294640,13
(R)-FTY720 methyl ether (ROMe),14 K145 (3-(2-amino-
ethyl)-5-[3-(4-butoxylphenyl)propylidene]thiazolidine-2,4-
dione),15 and SLR080811 ((S)-2-[3-(4-octylphenyl)-1,2,4-
oxadiazol-5-yl]pyrrolidine-1-carboximidamide)16 have Ki values
in the range of∼1−10 μM. Taken together, it is clear that there is
still a need to develop new SK1 and SK2 inhibitors, both to
increase the number of selective tools that can be used to
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interrogate the biology of these enzymes and to increase the
possibility of having useful new therapeutic agents to treat
disease.
In a recent study, we showed that RB-005 is a highly selective
SK1 inhibitor.7 Herein, we describe the synthesis of analogues of
the known SK1 inhibitors RB-005, FTY720,8 SKi,17 compounds
36a18,19 and 82,20 BML-258,5CB5468139,21 and SLR08081116
(Figure 2). These new analogues, which were designed to
possess some degree of structural similarity to the known
inhibitors, were evaluated through enzyme activity studies as
Figure 1. Structures of selected SK inhibitors.
Figure 2. Modiﬁcations introduced into the known SK inhibitors RB-005, SKi, SLR080811, 36a (VPC96091), and 82.
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inhibitors of SK1 and SK2. Structure−activity relationship
(SAR) studies are discussed, which are supported by an analysis
of molecular modeling poses of the inhibitors in the active site of
human SK1.
Table 1. Piperidyl Analogues of RB-005 Synthesized for Evaluation as SK Inhibitors
Table 2. Pyrrolidine Analogues of RB-005 Synthesized for Evaluation as SK Inhibitors
Table 3. Benzamide Analogues of RB-005 Synthesized for Evaluation as SK Inhibitors
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■ RESULTS AND DISCUSSION
The structures of the new compounds and their key structural
modiﬁcations are shown in Tables 1−4.
Chemical Synthesis. Linker Length. The synthetic routes
we employed to prepare compounds with one-, three-, and four-
carbon tethers are displayed in Scheme 1. The sole carbon atom
of the hydroxymethyl group of 4-iodobenzyl alcohol provided
the tether in RB-023, whereas the three carbons of propargyl
alcohol were the source of the tether in RB-024. In each of these
compounds, a Sonogashira reaction followed by catalytic
hydrogenation of the alkyne intermediate (1 and 3) and a SN2
reaction of a mesylate intermediate derived from 2 and 4 with 4-
hydroxypiperidine gave the desired compounds. We used 4-(4-
octylphenyl)butan-1-ol (5)22 as the starting material for the
preparation of RB-025.
Modiﬁcations of the 4-Alkylphenyl and the Piperidyl
Groups. Scheme 2 shows the synthetic pathways employed to
prepare RB-026−RB-033. After a Sonogashira reaction was used
to install an alkynyl group with 6−12 carbons, catalytic
hydrogenation of 6 and 7 aﬀorded alkyl derivatives 8 and 9,
and SN2 displacement as in Scheme 1 gave the desired
compounds in good yield. To assess the role of the hydroxyl
group in RB-005, RB-026, and RB-028 in inhibition of SK, we
replaced this group with an azido group via mesylation of the
alcohol and reaction with sodium azide inDMF to obtain 10,RB-
029, and RB-030. Reduction of the azide aﬀorded the amino
derivatives, RB-031, RB-032, and RB-033.
Fluorination of RB-005 with diethylaminosulfur triﬂuoride
(DAST) gave RB-034 in 90% yield (Scheme 3). The 4-keto
derivative RB-035 was synthesized by oxidation of the 4-
hydroxyl group of RB-005 with pyridinium chlorochromate.
Reaction of mesylate 117 with 4-methoxypiperidine provided
RB-036. Similarly, reaction of commercially available chiral
Table 4. Pyridine, Pyridinium, and Triazole Analogues of RB-005 Synthesized for Evaluation as SK Inhibitors
Scheme 1. Synthesis of RB-023−RB-025a
aReagents and conditions: (a) 1-octyne, Pd(PPh3)4, CuI, Et3N, 50 °C, 12 h; (b) Pd/C, H2, EtOAc, rt, 12 h; (c) (i) MsCl, Et3N, CH2Cl2, 3 h, rt; (ii)
4-hydroxypiperidine, MeCN, 50 °C, 12 h; (d) propargyl alcohol, Pd(PPh3)4, CuI, Et3N, 50 °C, 12 h.
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Scheme 2. Synthesis of RB-026−RB-033a
aReagents and conditions: (a) 1-hexyne or 1-dodecyne, Pd(PPh3)4, CuI, Et3N, 50 °C, 12 h; (b) Pd/C, H2, EtOAc; (c) (i) MsCl, Et3N, CH2Cl2; (ii)
4-hydroxypiperidine, MeCN, 50 °C, 12 h; (d) (i) MsCl, Et3N, CH2Cl2, 3 h, rt; (ii) NaN3, DMF, 80−100 °C, 12 h; (e) Pd/C, H2, CH2Cl2/MeOH
(1:3), rt, 12 h.
Scheme 3. Synthesis of RB-034−RB-043a
aReagents and conditions: (a) DAST, CH2Cl2, 0 °C to rt, 5 h, rt; (b) PCC, CH2Cl2, 4 h, rt; (c) cyclic amine, MeCN, 50 °C, 12 h.
Scheme 4. Synthesis of RB-044−RB-050 from 4-Iodobenzoic Acida
aReagents and conditions: (a) 1-octyne, Pd(PPh3)4, CuI, Et3N, 60 °C, 12 h; (b) Pd/C, H2, EtOAc, 12 h, rt; (c) (i) SOCl2, CH2Cl2, reﬂux, 12 h; (ii)
cyclic amine, K2CO3, MeCN, 50 °C, 12 h.
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pyrrolidines containing a 3-hydroxyl or a 2-hydroxymethyl
substituent gave RB-037−RB-043.
Benzamide Derivatives. Benzamide-containing analogues
RB-044−RB-050 were prepared from 4-iodobenzoic acid as
outlined in Scheme 4. Alkyne intermediate 12 was reduced to
carboxylate 13, which was converted to the acyl chloride with
thionyl chloride and then treated with the desired cyclic amine in
the presence of potassium carbonate.
Quaternary AmmoniumDerivatives.To synthesizeRB-052,
which contains a pyridinium ion in the polar headgroup, we used
the halogens in 1-bromo-4-iodobenzene to carry out two
separate Sonogashira reactions, as shown in Scheme 5. First,
we used 1-octyne to prepare alkyne 14, which reacted with 3-
ethynylpyridine to give dialkyne 15. Reduction of 15 yielded RB-
051, and N-alkylation with methyl iodide (5 equiv) in
acetonitrile aﬀorded the N-methylpyridinium salt RB-052.
Pyridinium salt RB-053 was prepared by a similar route, as
shown in Scheme 6. A Sonogashira reaction of 4-iodobenzyl
bromide with 1-octyne provided alkyne 16; displacement of
bromide ion with 4-(4-methylpiperidin-1-yl)pyridine (17)
aﬀorded alkyne 18, which provided RB-053 on catalytic
hydrogenation in MeOH/CH2Cl2 (1:3).
Triazole Derivatives. A Pd/Cu-catalyzed Sonogashira reac-
tion followed by a Cu(I)-catalyzed azide−alkyne 1,3-dipolar
addition (click reaction) was employed to prepare RB-054, in
which a triazole ring bearing a pyridine substituent is the
headgroup (Scheme 7). Thus, Sonogashira coupling of 1-octyne
with 4-iodoaniline aﬀorded alkynylaniline derivative 19. After
conversion of amine 19 to aryl azide 20, the triazole ring was
installed in a click reaction with 3-ethynylpyridine. Finally,
catalytic hydrogenation of alkyne 21 gave RB-054.
Scheme 5. Synthesis of RB-051 and RB-052 from 1-Bromo-4-iodobenzenea
aReagents and conditions: (a) 1-octyne, Pd(PPh3)4, CuI, Et3N, 50 °C, 12 h; (b) 3-ethynylpyridine, Pd(PPh3)4, CuI, Et3N, 80 °C, 3 days; (c) Pd/C,
H2, EtOAc, 12 h, rt; (d) K2CO3, MeI, MeCN, overnight, rt.
Scheme 6. Synthesis of Pyridinium Salt RB-053 from 4-Iodobenzyl Bromide and of 4-(4-Methylpiperidin-1-yl)pyridine (17) from
4-Chloropyridine Hydrochloridea
aReagents and conditions: (a) 1-octyne, Pd(PPh3)4, CuI, Et3N; (b) 4-methylpiperidine, DIPEA, MeCN, microwave heating, 160 °C, 1 h; (c) 17, 2-
butanone, 100 °C, 3 days; (d) Pd/C, H2, MeOH/CH2Cl2 (1:3).
Scheme 7. Synthesis of RB- 054 from 4-Iodoanilinea
aReagents and conditions: (a) 1-octyne, Pd(PPh3)4, CuI, Et3N, 60 °C, 12 h; (b) (i) 10% aq HCl, NaNO2; (ii) NaN3; (c) 3-ethynylpyridine, sodium
ascorbate, CuSO4, t-BuOH/H2O (1:1); (d) Pd/C, H2, EtOAc, rt, 2 days.
Journal of Medicinal Chemistry Article
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We reversed the location of the triazole in analogues RB057−
RB-065. As shown in Scheme 8, the headgroup in these
analogues is a piperidyl derivative and the lipophilic tail contains
an alkyl-substituted triazole. Azides 22 and 23 were prepared
from commercially available 4-aminophenol and 2-(4-
aminophenyl)ethanol, respectively. The click reaction with
terminal alkynes aﬀorded triazoles RB-055, 24, 25, and RB-
056. To prepare RB-059−RB-065, alcohols 24, 25, and RB-056
were converted to their corresponding mesylates 26, 27, and 28,
which were treated with piperidine, 1-methylpiperidine, or 4-
hydroxypiperidine.
Eﬀects on SK1 and SK2 Activity and SAR.We previously
demonstrated the importance of the 4-hydroxypiperidinyl group
in the selective inhibition of SK1,7 which was subsequently
conﬁrmed by Gustin et al., who generated chiral piperidyl
analogues bearing hydroxyl and hydroxymethyl groups.20 To
Scheme 8. Synthesis of RB-055−RB-065a
aReagents and conditions: (a) (i) 10% aq HCl, NaNO2; (ii) NaN3; (b) 1-decyne, sodium ascorbate, CuSO4, t-BuOH/H2O (1:1), 12 h, rt; (c)
acetylenic substrate (24, 1-hexyne; 25, 1-heptyne; RB-056, 1-decyne), sodium ascorbate, CuSO4, t-BuOH, H2O; (d) MsCl, Et3N, CH2Cl2, 0 °C to rt,
5 h; (e) piperidine, MeCN (RB-059−RB-061), 1-methylpiperidine, MeCN (RB-060−RB-062) or 4-hydroxypiperidine, MeCN, 50 °C, 12 h (RB-
063−RB-065).
Figure 3. Eﬀect of inhibitors on SK1 or SK2 activity. SK1 activity was measured using 3 μMSph and 250 μMATP. SK2 activity was assayed using 10 μM
Sph and 250 μMATP (n = 3 for each compound; results are expressed as % of control± SD). RB series compounds were used at 50 μM. BML-258 (50
μM) inhibited SK1 activity by 74.5 ± 3.3% (n = 3). The control is 100% and equals activity against Sph alone.
Journal of Medicinal Chemistry Article
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examine SAR among a panel of related compounds, we prepared
a series of analogues bearing a 4-hydroxypiperidinyl group but
varied the linker length between the aryl group and the
piperidine. We also assessed the role of the alkyl substituent in
the aryl group. To evaluate compound selectivity against SK1 or
SK2, the assays were performed (see Supporting Information)
using Sph at concentrations of 3 and 10 μM (the Km values of
SK1 and SK2, respectively), which corresponds to 50% substrate
saturation and enables a qualitative estimation of selectivity by
comparing the % inhibition of each kinase using a ﬁxed
concentration of inhibitor. We consider this approach to be an
appropriate comparison of selectivity, since both enzymes exhibit
50% occupancy with the substrate. Compounds that were found
to be eﬀective inhibitors were then analyzed in more detail by
performing dose−response curves.
We have previously shown that RB-005 (the “parent
compound”) is a selective inhibitor of SK1 and exhibits an IC50
= 3.6 ± 0.38 μM at 3 μM Sph (which corresponds to the Km of
SK1) and reduces SK1 activity by∼90% at 50 μM RB-005.7 The
eﬀect of linker length on potency was assessed by comparing the
% inhibition of SK1 and SK2 obtained with RB-023 (which has a
one-carbon tether), RB-024 (three-carbon tether), and RB-025
(four-carbon tether). The linker length did not signiﬁcantly alter
the ability of RB-023, RB-024, and RB-025 to inhibit SK1
activity (Figure 3). RB-023−RB-025 also retained selectivity for
SK1 over SK2.
The aliphatic chain at the para position of the benzene ring of
FTY720 is C8H17, which is known to be optimal for the action of
FTY720 on its targets such as S1P receptors.23 Knott et al.24
reported that the ability of quaternary ammonium salts with a
phenyl-substituted cyclohexylamine scaﬀold to inhibit SK2 was
aﬀected by the alkyl chain length. To examine the role of the alkyl
substituent on the benzene ring of RB-005, and thus the
lipophilicity of the molecule, we compared the inhibitory activity
of RB-026 (which has a methyl group as the alkyl substituent),
RB-027 (which has a n-hexyl group), RB-005 (which has a n-
octyl group), and RB-028 (which has a n-dodecyl group). SK1
inhibition was decreased by more than 6-fold in RB-026
compared with RB-023. The almost complete lack of inhibition
displayed by RB-026 against SK1 indicates that a larger alkyl
group than a methyl group is required for inhibitory activity. We
also evaluated the eﬀect of alkyl chain length in the lipophilic tail
of compounds in which the 4-hydroxypiperidinyl group was
replaced by a 4-aminopiperidinyl group (see below). Changing
the n-octyl group of RB-032 to a methyl or n-dodecyl group gave
RB-031 and RB-033, respectively, and eliminated the inhibitory
activity toward SK1. These results conﬁrm the critical require-
ment for the n-octyl group.
Next, we probed the role of the 4-hydroxyl group ofRB-005 by
replacing it with an azido, amino, ﬂuoro, keto, or methoxy group
(RB-029−RB-036). Azido replacement (RB-029, RB-030)
reduced SK1 inhibition markedly, while replacement of the 4-
hydroxyl group with an amino group (RB-032) diminished the
potency of SK1 inhibition (Figure 4). The isoform selectivity of
SK1 over SK2 was retained for RB-032, suggesting that the
amino group replacement maintains eﬃcient binding to SK1.
Replacement of the 4-hydroxyl group of RB-005 with a ﬂuoro
(RB-034) or methoxy group (RB-036) eliminated inhibitory
activity against SK1, while replacement with a keto group to
produce RB-035 increased inhibition of SK2 and maintained
inhibition of SK1 but eliminated the isoform selectivity.
To examine the role of the piperidyl group in inhibition of SK,
we replaced it with a pyrrolidine ring; the hydroxyl-containing
substituent was retained (as either a chiral hydroxyl or a chiral
hydroxymethyl group), but its orientation was varied, as shown in
compounds RB-037−RB-043. RB-037 and RB-038 retained
inhibitory activity against SK1 despite having opposite
conﬁgurations at C-3 of the pyrrolidin-3-ol group. Stereoisomers
RB-040 and RB-042, which diﬀer in the length of the aliphatic
chain (C8H17 vs C12H5) but possess the R conﬁguration at C-2 of
the 2-hydroxymethylpyrrolidinyl group, were equipotent inhib-
itors of SK1 and SK2 (Figure 3 and Figure 5). The corresponding
S enantiomers RB-041 and RB-043 were much less active
(Figure 3). To establish whether RB-041 and RB-043 were
capable of inhibiting SK1 and SK2 activity in a concentration-
dependent manner, we used a higher concentration of each (100
μM, compared to the 50 μM concentration data shown in Figure
3), and found that the inhibition of SK1 and SK2 with RB-041
was 72.2± 5.9% and 45.7± 2.6%, respectively, whereas withRB-
043 the inhibition of SK1 and SK2 was 49.9 ± 6.2% and 49.7 ±
7%, respectively. These ﬁndings indicate that RB-041 and RB-
043 can inhibit SK1 and SK2 but that the sensitivity of inhibition
compared with RB-040 and RB-042 is considerably reduced.
Interestingly, the S enantiomers RB-041 and RB-043 are
substrates for SK2 (see Supporting Information, Figure S1).
To further examine the inﬂuence of the length of the alkyl
substituent on the benzene ring on SK activity, we assessed the
extent of SK inhibition aﬀorded by pyrrolidine derivatives RB-
039, RB-042, and RB-043. The ability of the compound to
inhibit SK1 is abolished in RB-039 and RB-043, which have a
methyl and a n-dodecyl group in the lipophilic tail, respectively.
An amidine or proline headgroup incorporated into a
benzamide-containing scaﬀold was shown to provide potent
SK1 inhibitors,18,19 as in compound 36a (Figure 1). When we
replaced the methylene linker between the aryl group and the
heterocycle with a keto group to produce the benzamide
analogues RB-044−RB-050, inhibition of SK1 was eﬀectively
abolished (Figure 3), as were the pyridine derivatives (RB-048
and RB-051). The report that quaternary ammonium salts are
selective SK2 inhibitors25 prompted us to prepare RB-052, RB-
053, RB-060, RB-061, andRB-062, which were ineﬀective as SK
inhibitors, althoughRB-053 demonstrated a moderate selectivity
for SK2 (Figure 3). We also prepared aliphatic quaternary
ammonium salts (not shown) that were inactive.
SK inhibitors containing a central thiazole group have been
reported (e.g., SKi and compound 82, Figure 1). 1,2,3-Triazoles
are mimics of thiazoles and are easily prepared by Cu(I)-
catalyzed azide/alkyne click chemistry. In our series of triazole
Figure 4. Eﬀect of RB-032 on SK1 activity. Concentration-dependent
inhibition of SK1 activity by RB-032 using 3 μM Sph and 250 μMATP.
The results are expressed as % of control ± SD; n = 3. The control is
100% and equals activity against Sph alone.RB-032 inhibits SK1 activity
with IC50 = 16.9 ± 1.6 μM. RB-005 inhibits SK1 activity with IC50 = 3.6
± 0.36 μM.7
Journal of Medicinal Chemistry Article
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Figure 5. Eﬀect of RB-040 and RB-042 on (A) SK1 activity and (B) SK2 activity. Concentration-dependent inhibition of SK activity by RB-040 and
RB-042 using 3 μMSph (SK1) or 10 μMSph (SK2) and 250 μMATP. The results are expressed as % of control± SD (n = 3). The control is 100% and
equals activity against Sph alone. RB-040 inhibits SK1 activity with IC50 = 2.2 ± 0.22 μM and SK2 activity with IC50 = 5.2 ± 0.82 μM. RB-042 inhibits
SK1 activity with IC50 = 5.3 ± 0.5 μM and SK2 activity with IC50 = 5.0 ± 1.3 μM.
7
Figure 6. Various modeled poses of SK1 inhibitors in the catalytic site of SK1: (A) RB-005, (B) RB-025, (C) RB-028, (D) RB-032, (E) RB-033, (F)
RB-040, (G) RB-042, and (H) RB-065. Dotted lines represent hydrogen bonds.
Journal of Medicinal Chemistry Article
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analogues ofRB-005 (RB-054−RB-065), we found thatRB-065
was a highly selective SK1 inhibitor, whereas the other 10 triazole
analogues, all of which lack the 4-hydroxypiperidinyl group, were
inactive (Figure 3).
Modeling the Inhibitors in the Atomic Structure of
SK1. The crystal structures of human SK1 in a complex with
ADP and SKi were determined recently.26 We demonstrate here
that the chemical modiﬁcations of the highly selective SK1
inhibitor RB-005 produced SAR that can be explained using this
crystal structure. Figure 6A displays the result of a modeling
analysis of RB-005 in the active site of human SK1; the piperidyl
hydroxyl group is hydrogen-bonded to D81, and the protonated
amine of the headgroup forms a salt bridge with the carboxylate
of D178. Fluoro (RB-034) or methoxy (RB-036) containing
compounds do not exhibit inhibitory activity against SK1 (Figure
3), as these groups no longer have hydrogen bond donating
capacity, suggesting that the interaction of the 4-hydroxypiper-
idinyl group of RB-005 is with a hydrogen bond acceptor in the
protein. The lack of SK1 inhibitor activity of the azide-containing
compounds (RB-029, RB-030) supports this possibility. One of
the two oxygens of the carboxylate ion of D81 is hydrogen-
bonded to the backbone NH of L116, and the other is hydrogen-
bonded to the backbone NH of A115; these interactions prevent
the carboxylate of D81 from being catalytic and shift the catalytic
role to D178 (Figure 7). The latter carboxylate oxygen also forms
a hydrogen bond to the hydroxyl group of the inhibitor. If these
compounds formed hydrogen bonds with the side chain of S168,
then RB-029, RB-034, and RB-036 could also bind to the
donor/acceptor hydroxyl group of S168 or water and therefore
act as inhibitors. Since RB-029, RB-034, and RB-036 cannot
form hydrogen bonds with D81 and are not inhibitors, we
propose that the key interaction of the hydroxyl group ofRB-005
(Figure 6A), RB-025 (Figure 6B), and RB-028 (Figure 6C) is
with D81 and not with S168. In contrast, modeling of RB-035
(which contains a 4-keto group instead of a 4-hydroxyl group, yet
maintains inhibition of SK1) suggests that the carbonyl group
can form a hydrogen bond with the hydroxyl group of S168 and
water (see Supporting Information, Figure S2).
The inhibitory eﬀect of RB-032 (Figure 6D) and its absence
for RB-033 (Figure 6E) can be explained by protonation of the
primary amine. When the protonated primary amine rather than
the piperidyl group forms a salt bridge with D178, the inhibitors
are pushed deeper into the J channel, which was identiﬁed by
Wang et al.26 as the region that accommodates the alkyl chain of
Sph. Since RB-032 has a shorter alkyl chain than RB-033, it can
be accommodated in the substrate pocket, whereas the dodecyl
group of RB-033 cannot ﬁt into the channel formed when the
protonated primary amine forms a salt bridge with D178.
Therefore, RB-033, which is inactive, does not bind to D81,
D178, S168, or L268, indicating that these are key amino acid
residues required for binding SK inhibitors.
The salt bridge between the NH3
+ group of RB-032 and D178
(Figure 6D) is the only polar interaction with the protein, which
might explain the lower SK1 inhibitor activity when compared
with RB-005; the latter forms a salt bridge and hydrogen-bonds
with D81. Interestingly, the R-enantiomers RB-040 and RB-042
are equipotent inhibitors of SK1 and SK2, while the S-
enantiomers RB-041 and RB-043 are weak substrates for SK2,
implying that the spatial orientation of the hydroxyl group inRB-
041 and RB-043 required for catalysis is diﬀerent in SK2
compared with SK1. The protonated amine in RB-040 (Figure
6F) and RB-042 (Figure 6G) can form a salt bridge with D178
and can also form a hydrogen bond with the carbonyl oxygen of
L268. Both inhibitors can orientate the hydroxymethyl group of
the pyrrolidine (R enantiomer) to also form a hydrogen bond
with the side chain of D81. The protonated amino group of RB-
041 andRB-043 can form a salt bridge with D178 but, because of
the orientation of the hydroxymethyl group of the pyrrolidine (S
enantiomer), cannot form a hydrogen bond between their
hydroxyl group and D81, as found in our modeling study.
Instead, the hydroxymethyl group could form a hydrogen bond
to D178. As the experimental evidence shows that RB-041 and
RB-043 do not inhibit SK1, this suggests that dynamic factors
(accessing the binding site), which are not taken into account by
docking studies, prevent the binding of these compounds.
RB-044−RB-050 are ineﬀective inhibitors of SK1. There are
three possible explanations: ﬁrst, the nitrogen in an amide cannot
be protonated, thus preventing salt bridge formation. Second, the
link between nitrogen and phenyl is constrained and planar
compared with a methylene group, which prevents optimization
of the hydrogen bonding network with the hydroxyl group.
Third, the carbonyl group of the amide would be proximal to the
side chain of D178, which would result in electrostatic repulsion.
The pyridinium salts RB-052 and RB-053 and the quaternary
ammonium salts RB-060, RB-061, and RB-062 were also
ineﬀective SK1 inhibitors. The absence of a hydroxyl group in
these compounds rules out hydrogen bonding with D81 or
D178. The triazole moiety in RB-065 forms a hydrogen bond
with T196 (Figure 6H) and, furthermore, adds a kink in the chain
that helps orientate the alkyl group into the J channel, which may
account for its SK1 inhibitory activity.
Our modeling studies suggest that RB-005 (Figure 6A), RB-
025 (Figure 6B), andRB-028 (Figure 6C) interact with D81 and
not with S168. These ﬁndings are consistent with D81 not acting
as a base, becauseRB-005,RB-025, orRB-028 are not substrates
for SK1. As depicted in Figure 7, modeling of Sph into the
catalytic site of SK1 suggests that S168 can form hydrogen bonds
Figure 7. Schematic model of the proposed mechanism of the
phosphorylation of Sph catalyzed by SK1.
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with the NH3
+ group of Sph and, via a water molecule, with the
secondary hydroxyl group of Sph. The water molecule also
hydrogen-bonds with A339, thereby linking this amino acid
residue to the secondary hydroxyl group of Sph (Figure 7). Thus,
D178 functions as the deprotonating base in this model to enable
nucleophilic attack by Sph on the γ-phosphate group of ATP,
with subsequent transfer of this phosphate to Sph.
■ CONCLUSION
In this study we have identiﬁed a series of SK1-selective
inhibitors and have used molecular modeling to deﬁne their
interactions with the catalytic site of the enzyme. These studies
reveal a substantial ﬂexibility in the catalytic site in terms of
binding SK1 inhibitors. For instance, RB-005 is proposed to
interact with D81 and D178, while RB-025 appears to interact
with D81 and L268. The ﬁndings obtained from the modeling
study fully account for the SAR of the inhibitors and explain why
some of these compounds are inactive. These ﬁndings also reveal
the architecture of the SK1 catalytic site and suggest a major role
for D178 as the deprotonating base that facilitates phosphor-
ylation of Sph by ATP. In summary, the novel information
presented here should enable development of new SK1
inhibitors with improved potency and selectivity. Similarly,
resolution of the atomic structure of SK2 (yet to be achieved)
along with information provided herein will enable better
insights into the molecular basis of the selectivity of these
inhibitors for SK1 over SK2.
■ EXPERIMENTAL SECTION
Docking Studies. The crystal structure of SK1 in complex with Sph
(PDB entry 3VZB) was used for docking studies. Chain A of the
complex was kept along with a single water molecule found to be tightly
bound to the complex which hydrogen-bonds to the side chain hydroxyl
group of S168, the backbone−NHof G342, and the secondary hydroxyl
group of Sph (water number 680). Hydrogen atoms were added to the
protein and water using Accelrys Discovery Studio 3.1 (Accelrys
Software, San Diego, CA), and all of the inhibitors presented in this
study were docked using GOLD 5.1 for Windows (Cambridge
Crystallographic Data Centre, Cambridge, U.K.). Default software
settings were used, keeping ChemPLP as a scoring function after
redocking Sph in place in the 3VZB crystal structure as well as the SKi
inhibitor in the 3VZD PDB entry (rmsd of 1.8 and 0.2 Å, respectively) as
validation.
Synthesis. General Methods. All chemicals were reagent grade
and used as purchased. Reactions were run under nitrogen and were
monitored by TLC using silica gel 60 F254 aluminum-backed plates.
Flash column chromatography was performed on silica gel grade 60
(230−400 mesh). THF was distilled over sodium/benzophenone
immediately prior to use. Dichloromethane was distilled over CaH2, and
Et3N was distilled over KOH pellets. All other solvents were of
anhydrous quality and were used as received. 1H NMR and 13C NMR
spectra were recorded on a Bruker Avance I spectrometer, and chemical
shifts are reported in δ units relative to deuterated solvents, which served
as internal references, at 400 and 100 MHz, respectively. High-
resolution mass spectra were recorded at the CUNYMass Spectrometry
Facility on an Agilent Technologies G6520AQ-TOFmass spectrometer
using electrospray ionization (ESI). Microwave reactions were
performed in a Biotage Emrys Creator synthesizer. HPLC was carried
out using a reverse-phase column with a gradient of acetonitrile/water
from 50/50 to 90/10, with detection at 214 and 254 nm. Elemental
analysis was performed at Columbia Analytical Services, Tucson, AZ. All
compounds were ≥95% pure as determined by examining their HRMS
and 1H NMR spectra.
(4-(Oct-1-ynyl)phenyl)methanol (1). To a solution of 4-
iodobenzyl alcohol (200 mg, 0.85 mmol), bis(triphenylphosphine)-
palladium dichloride (49 mg, 0.040 mmol), and copper(I) iodide (7.6
mg, 0.04 mmol) in anhydrous triethylamine (10 mL) was added 1-
octyne (283 mg, 2.56 mmol) at room temperature. After the reaction
mixture was heated at 50 °C for 12 h, saturated aqueous ammonium
chloride solution was added, and the mixture was extracted with EtOAc.
The combined solution was washed with water, brine, and dried. Flash
column chromatography with hexanes/EtOAc (5:1) as the eluent gave
alkyne 1 (180 mg, 98%) as a yellow oil. 1H NMR (400 MHz, CDCl3) δ
0.90 (t, J = 6.9 Hz, 3H), 1.28−1.36 (m, 4H), 1.41−1.49 (m, 2H), 1.60
(quin, J = 7.3 Hz, 2H), 1.89 (br s, 1H), 2.40 (t, J = 7.1 Hz, 2H), 4.65 (s,
2H), 7.25 (d, J = 8.1 Hz, 2H), 7.37 (d, J = 8.1 Hz, 2H); 13C NMR (100
MHz, CDCl3) δ 14.1, 19.4, 22.6, 28.6, 28.7, 31.4, 65.0, 80.3, 90.6, 123.4,
126.8, 131.7, 140.1; ESI-HRMS (M + H)+ m/z calcd for C15H21O
217.1592, found 217.1588.
(4-Octylphenyl)methanol (2).Compound 1 (180 mg, 0.83 mmol)
was dissolved in EtOAc (10 mL), and 10% Pd/C (90 mg, 50 wt %) was
added. The reaction mixture was hydrogenated at room temperature for
12 h. The catalyst was removed by ﬁltration through a pad of Celite,
which was rinsed with EtOAc. Product 2 was obtained, without
puriﬁcation, as a colorless oil. 1H NMR (400MHz, CDCl3) δ 0.87 (t, J =
6.6 Hz, 3H), 1.26−1.30 (m, 10H), 1.56−1.63 (m, 2H), 1.78 (br s, 1H),
2.59 (t, J = 7.7Hz, 2H), 4.64 (s, 2H), 7.16 (d, J = 8.0Hz, 2H), 7.26 (d, J =
8.0 Hz, 2H); 13C NMR (100MHz, CDCl3) δ 14.1, 22.7, 29.3, 29.4, 29.5,
31.6, 31.9, 35.7, 65.3, 127.1, 128.6, 138.1, 142.6; ESI-HRMS (M + H)+
m/z calcd for C15H25O 221.1905, found 221.1887.
1-(4-Octylbenzyl)piperidin-4-ol (RB-023). To a solution of 2 (37
mg, 0.17 mmol) and triethylamine (0.23 mL, 1.7 mmol) in CH2Cl2 (5
mL) at 0 °C was added methanesulfonyl chloride (40 μL, 0.50 mmol).
After being stirred at room temperature for 3 h, the reaction mixture was
evaporated, diluted with water, and the product was extracted with
EtOAc. The extract was washed with brine, dried, and evaporated. To a
solution of the reaction mixture (0.17 mmol) in MeCN (3 mL) was
added 4-hydroxypiperidine (86 mg, 0.85 mmol). The reaction mixture
was stirred at 50 °C for 12 h and concentrated. Puriﬁcation by silica gel
chromatography, eluting with CH2Cl2/MeOH (5:1), gave 35 mg (69%,
two steps) of RB-023 as a colorless oil. 1H NMR (400 MHz, CDCl3) δ
0.88 (t, J = 6.8 Hz, 3H), 1.23−1.30 (m, 10H), 1.56−1.73 (m, 4H), 1.97−
2.06 (m, 2H), 2.35−2.47 (m, 2H), 2.59 (t, J = 7.7 Hz, 2H), 2.85−2.90
(m, 2H), 3.64 (s, 2H), 3.78−3.81 (m, 1H), 7.15 (d, J = 7.9 Hz, 2H), 7.27
(d, J = 8.0 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 14.1, 22.7, 29.3,
29.4, 29.5, 31.5, 31.9, 33.2, 35.7, 50.1, 62.2, 128.5, 129.7, 137.2, 142.8;
ESI-HRMS (M + H)+ m/z calcd for C20H34NO 304.2640, found
304.2637.
3-(4-Octylphenyl)prop-2-yn-1-ol (3). Compound 3 was prepared
from 1-bromo-4-n-octylbenzene and propargyl alcohol according to a
Sonogashira reaction procedure similar to that described for 1. Yield =
82%; 1H NMR (400MHz, CDCl3) δ 0.86 (t, J = 6.8 Hz, 3H), 1.22−1.30
(m, 10H), 1.57−1.60 (m, 2H), 2.59 (t, J = 7.7 Hz, 2H), 4.49 (s, 2H),
7.11 (d, J = 7.8 Hz, 2H), 7.34 (d, J = 7.7 Hz, 2H); 13C NMR (100 MHz,
CDCl3) δ 14.1, 22.7, 29.2, 29.4, 31.2, 31.9, 35.9, 51.7, 85.9, 86.5, 119.6,
128.4, 131.6, 143.7; ESI-HRMS (M + H)+ m/z calcd for C17H25O
245.1905, found 245.1903.
3-(4-Octylphenyl)propan-1-ol (4). Compound 4 was prepared
from 3 by a catalytic hydrogenation procedure similar to that described
for 2. 1H NMR (400MHz, CDCl3) δ 0.88 (t, J = 6.8 Hz, 3H), 1.24−1.30
(m, 10H), 1.59 (quin, J = 7.4 Hz, 2H), 1.88 (quin, J = 6.5 Hz, 2H), 2.56
(t, J = 7.7 Hz, 2H), 2.67 (t, J = 7.7 Hz, 2H), 3.66 (t, J = 6.4 Hz, 2H), 7.10
(s, 4H); 13C NMR (100 MHz, CDCl3) δ 14.1, 22.7, 29.3, 29.4, 29.5,
31.6, 31.7, 31.9, 34.3, 35.6, 62.4, 128.3, 128.4, 138.9, 140.5; ESI-HRMS
(M + H)+ m/z calcd for C17H29O 249.2218, found 249.2210.
1-(3-(4-Octylphenyl)propyl)piperidin-4-ol (RB-024). Com-
pound RB-024 was prepared from 4 according to a procedure similar
to that described forRB-023. Yield = 73%; 1HNMR (400MHz, CDCl3)
δ 0.87 (t, J = 6.8 Hz, 3H), 1.25−1.30 (m, 10H), 1.55−1.65 (m, 4H),
1.79−1.92 (m, 4H), 2.16−2.20 (m, 2H), 2.40−2.43 (m, 2H), 2.53−2.63
(m, 4H), 2.80−2.83 (m, 2H), 3.67−3.69 (m, 1H), 7.08 (s, 4H); 13C
NMR (100 MHz, CDCl3) δ 14.1, 22.7, 28.5, 29.3, 29.4, 29.5, 31.6, 31.9,
33.3, 34.0, 35.6, 50.9, 57.9, 128.2, 128.4, 138.9, 140.4; ESI-HRMS (M +
H)+ m/z calcd for C22H38NO 332.2953, found 332.2951.
1-(4-(4-Octylphenyl)butyl)piperidin-4-ol (RB-025). Compound
RB-025 was prepared from 4-(4-octylphenyl)butan-1-ol (5)22 accord-
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ing to a procedure similar to that described for compoundRB-023. Yield
= 67% (two steps); 1H NMR (400 MHz, CDCl3) δ 0.88 (t, J = 6.9 Hz,
3H), 1.24−1.33 (m, 10H), 1.55−1.68 (m, 4H), 1.80−1.88 (m, 4H),
2.21−2.26 (m, 2H), 2.56 (t, J = 7.8 Hz, 2H), 2.61 (t, J = 7.5 Hz, 2H),
2.71−2.89 (m, 4H), 3.11 (t, J = 9.0 Hz, 2H), 3.97−4.01 (m, 1H), 7.05
(d, J = 8.4 Hz, 2H), 7.09 (d, J = 8.4 Hz, 2H); 13C NMR (100 MHz,
CDCl3) δ 14.1, 22.7, 28.9, 29.3, 29.4, 29.5, 31.6, 31.9, 34.9, 35.6, 57.5,
128.2, 128.5, 138.6, 140.7; ESI-HRMS (M + H)+ m/z calcd for
C23H40NO 346.3110, found 346.3107.
2-(4-(Hex-1-ynyl)phenyl)ethanol (6). Compound 6 was prepared
from 2-(4-bromophenyl)ethanol and 1-hexyne according to a
Sonogashira procedure similar to that described for 1. Yield = 60%;
1H NMR (400 MHz, CDCl3) δ 0.95 (t, J = 7.3 Hz, 3H), 1.43−1.52 (m,
2H), 1.55−1.62 (m, 2H), 2.40 (t, J = 7.0 Hz, 2H), 2.85 (t, J = 6.5 Hz,
2H), 3.84 (t, J = 6.5 Hz, 2H), 7.14 (d, J = 8.1 Hz, 2H), 7.34 (t, J = 8.1 Hz,
2H); 13C NMR (100 MHz, CDCl3) δ 13.7, 19.1, 22.0, 29.7, 30.9, 39.0,
63.5, 80.3, 90.2, 122.3, 128.9, 131.7, 137.9; ESI-HRMS (M + H)+ m/z
calcd for C14H19O 203.1436, found 203.143 33.
2-(4-(Dodec-1-ynyl)phenyl)ethanol (7). Compound 7 was
prepared from 2-(4-bromophenyl)ethanol and 1-decyne according to
a procedure similar to that described for 1. Yield = 62%; 1H NMR (400
MHz, CDCl3) δ 0.88 (t, J = 6.8 Hz, 3H), 1.23−1.30 (m, 12H), 1.40−
1.45 (m, 2H), 1.59 (quin, J = 7.3 Hz, 2H), 2.38 (t, J = 7.1 Hz, 2H), 2.81
(t, J = 6.6 Hz, 2H), 3.79 (t, J = 6.5 Hz, 2H), 7.11 (d, J = 8.2 Hz, 2H), 7.32
(d, J = 8.1 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 14.1, 19.4, 22.7,
24.9, 28.8, 29.0, 29.2, 29.4, 29.6, 31.9, 39.0, 63.4, 80.4, 90.2, 122.3, 128.6,
131.4, 138.0; ESI-HRMS (M + H)+ m/z calcd for C20H31O 287.2375,
found 287.2371.
2-(4-Hexylphenyl)ethanol (8). Compound 8 was prepared from 6
according to a procedure similar to that described for 2. 1H NMR (400
MHz, CDCl3) δ 0.88 (t, J = 6.6 Hz, 3H), 1.22−1.37 (m, 6H), 1.55−1.63
(m, 2H), 2.57 (t, J = 7.8 Hz, 2H), 2.84 (t, J = 6.6 Hz, 2H), 3.84 (t, J = 6.5
Hz, 2H), 7.13 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 14.1, 22.6, 29.0,
31.5, 31.7, 35.6, 38.8, 63.8, 128.6, 128.9, 135.5, 141.2; ESI-HRMS (M +
H)+ m/z calcd for C14H23O 207.1749, found 207.1725.
2-(4-Dodecylphenyl)ethanol (9). Compound 9 was prepared
from 7 according to a procedure similar to that described for 2. 1HNMR
(400 MHz, CDCl3) δ 0.88 (t, J = 6.8 Hz, 3H), 1.23−1.31 (m, 18H),
1.57−1.60 (m, 2H), 2.56 (t, J = 7.8Hz, 2H), 2.81 (t, J = 6.6Hz, 2H), 3.81
(t, J = 6.6 Hz, 2H), 7.12 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 14.1,
22.7, 29.4, 29.6, 29.7, 31.6, 31.9, 35.6, 38.8, 63.7, 128.6, 128.9, 135.5,
141.2; ESI-HRMS (M + Na)+ m/z calcd for C20H34ONa 313.2507,
found 313.2502.
1-(4-Methylphenethyl)piperidin-4-ol (RB-026). Compound
RB-026 was prepared from 2-(4-methylphenyl)ethanol according to a
procedure similar to that described for RB-023. Yield = 69%; 1H NMR
(400 MHz, CDCl3) δ 1.69−1.77 (m, 2H), 1.99−2.04 (m, 2H), 2.31 (s,
3H), 2.48−2.52 (2H), 2.72−2.76 (m, 2H), 2.79 (s, 1H), 2.84−2.88 (m,
2H), 2.98−3.03 (m, 2H), 3.78−3.84 (m, 1H), 7.10 (s, 4H); ESI-HRMS
(M + H)+ m/z calcd for C14H22NO 220.1701, found 220.1699.
1-(4-Hexylphenethyl)piperidin-4-ol (RB-027). Compound RB-
027 was prepared from 8 according to a procedure similar to that
described forRB-023. Yield = 79%; 1HNMR (400MHz, CDCl3) δ 0.88
(t, J = 6.5 Hz, 3H), 1.26−1.36 (m, 6H), 1.58 (quin, J = 7.4 Hz, 2H),
1.75−1.80 (m, 2H), 2.08−2.13 (m, 2H), 2.56 (t, J = 7.7 Hz, 2H), 2.74−
2.77 (m, 2H), 2.90−2.94 (m, 2H), 3.00−3.04 (m, 2H), 3.86−3.90 (m,
1H), 7.11 (s, 4H); 13C NMR (100MHz, CDCl3) δ 14.1, 22.6, 29.0, 31.5,
31.7, 35.6, 50.1, 59.9, 128.5, 128.6, 141.2; ESI-HRMS (M + H)+ m/z
calcd for C19H32NO 290.2484, found 290.2478.
1-(4-Dodecylphenethyl)piperidin-4-ol (RB-028). Compound
RB-028 was prepared from 9 according to a procedure similar to that
described forRB-023. Yield = 75%; 1HNMR (400MHz, CDCl3) δ 0.88
(t, J = 6.6 Hz, 3H), 1.23−1.33 (m, 18H), 1.56−1.60 (m, 2H), 1.67−1.72
(m, 2H), 1.98−2.01 (m, 2H), 2.34−2.39 (m, 2H), 2.56 (t, J = 7.4 Hz,
2H), 2.64−2.68 (m, 2H), 2.81−2.84 (m, 2H), 2.91−2.95 (m, 2H),
3.75−3.79 (m, 1H), 7.10 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 14.1,
22.7, 29.4, 29.5, 29.6, 29.7, 31.6, 31.9, 32.8, 35.6, 50.6, 60.3, 128.5, 136.7,
140.9; ESI-HRMS (M + H)+ m/z calcd for C25H44NO 374.3423, found
374.3414.
4-Azido-1-(4-methylphenethyl)piperidine (RB-029). To a
solution of RB-026 (115 mg, 0.52 mmol) and triethylamine (0.73
mL, 5.24 mmol) in CH2Cl2 (5 mL) at 0 °C was added methanesulfonyl
chloride (0.12 mL, 1.57 mmol). After being stirred at room temperature
for 4 h, the reaction mixture was evaporated, diluted with water, and the
product was extracted with EtOAc. The extract was washed with brine,
evaporated, and dried. To a solution of reactionmixture in 5mL of DMF
was added sodium azide (170mg, 2.62mmol). The reactionmixture was
stirred at 80 °C for 12 h and then concentrated. The residue was
dissolved in EtOAc, and the organic phase was evaporated and dried.
Puriﬁcation by silica gel chromatography, eluting with hexane/EtOAc
(1/1), gave 79 mg (62%) of RB-029 as a colorless oil. 1H NMR (400
MHz, CDCl3) δ 1.69−1.78 (m, 2H), 1.96−1.99 (m, 2H), 2.30−2.35 (m,
2H), 2.31 (s, 3H), 2.60−2.65 (m, 2H), 2.76−2.80 (m, 2H), 2.86−2.89
(m, 2H), 3.44−3.48 (m, 1H), 7.09 (s, 4H); 13C NMR (100 MHz,
CDCl3) δ 21.0, 29.4, 30.5, 33.0, 50.9, 57.3, 60.4, 128.6, 129.2, 132.4,
135.7, 136.7; ESI-HRMS (M + H)+ m/z calcd for C14H21N4 245.1766,
found 245.1763.
4-Azido-1-(4-octylphenethyl)piperidine (RB-030). Compound
RB-030was prepared from RB-0057 according to a procedure similar to
that described for RB-029. Yield = 71%; 1H NMR (400 MHz, CDCl3) δ
0.87 (t, J = 6.8 Hz, 3H), 1.24−1.31 (m, 10H), 1.58 (quin, J = 7.2 Hz,
2H), 1.67−1.76 (m, 2H), 1.93−1.97 (m, 2H), 2.24−2.29 (m, 2H),
2.54−2.61 (m, 4H), 2.75−2.79 (m, 2H), 2.84−2.90 (m, 2H), 3.40−3.46
(m, 1H), 7.10 (s, 4H); 13C NMR (100 MHz, CDCl3) δ 14.1, 22.7, 29.3,
29.4, 29.5, 29.7, 30.3, 30.7, 31.6, 31.9, 33.2, 35.6, 51.1, 57.6, 60.5, 128.5,
137.2, 140.8; ESI-HRMS (M + H)+ m/z calcd for C21H35N4 343.2862,
found 343.2857.
1-(4-Methylphenethyl)piperidin-4-amine (RB-031). To a sol-
ution of RB-029 (30 mg, 0.12 mmol) in MeOH/CH2Cl2 (1/3, 3 mL)
was added 10% Pd/C (50 wt %). The reaction mixture was
hydrogenated at room temperature for 12 h. The catalyst was removed
by ﬁltration through a pad of Celite, which was rinsed with MeOH/
CH2Cl2 (3/1). The residue was washed with EtOAc/hexane (1/1),
evaporated, and dried. RB-031 was obtained as a white solid. 1H NMR
(400 MHz, CD3OD) δ 1.82−1.90 (m, 2H), 2.17 (d, J = 10.2 Hz, 2H),
2.28 (s, 3H), 2.34 (t, J = 10.6 Hz, 2H), 2.68−2.71 (m, 2H), 2.79−2.83
(m, 2H), 3.13 (d, J = 11.2Hz, 2H), 3.13−3.20 (m, 1H), 7.07 (s, 4H); 13C
NMR (100 MHz, CDCl3) δ 21.0, 30.7, 32.4, 48.2, 51.4, 59.8, 128.6,
129.2, 135.8, 136.0; ESI-HRMS (M + H)+ m/z calcd for C14H23N2
219.1861, found 219.1858.
1-(4-Octylphenethyl)piperidin-4-amine (RB-032). Compound
RB-032 was prepared from RB-030 according to a procedure similar to
that described for RB-031. 1H NMR (400 MHz, CD3OD) δ 0.91 (t, J =
6.8 Hz, 3H), 1.28−1.34 (m, 10H), 1.61 (quin, J = 6.5 Hz, 2H), 2.06−
2.15 (m, 2H), 2.32 (d, J = 13.2 Hz, 2H), 2.60 (t, J = 7.52 Hz, 2H), 3.08−
3.14 (m, 2H), 3.24 (t, J = 11.5 Hz, 2H), 3.35−3.38 (m, 2H), 3.51−3.58
(m, 1H), 3.76 (d, J = 11.8 Hz, 2H), 7.17 (d, J = 8.0 Hz, 2H), 7.23 (d, J =
8.0 Hz, 2H); 13C NMR (100 MHz, CD3OD) δ 14.4, 23.7, 30.3, 30.4,
30.6, 31.1, 32.7, 33.0, 36.5, 36.9, 129.8, 129.9, 134.7, 143.2; ESI-HRMS
(M + H)+ m/z calcd for C21H37N2 317.2957, found 317.2951.
1-(4-Dodecylphenethyl)piperidin-4-amine (RB-033). To a
solution of RB-028 (20 mg, 0.050 mmol) and triethylamine (70 μL,
0.54 mmol) in CH2Cl2 (3 mL) at 0 °C was added methanesulfonyl
chloride (10 μL, 0.15 mmol). After being stirred at room temperature
for 4 h, the reaction mixture was evaporated, diluted with water, and the
product was extracted with EtOAc. The extract was washed with brine,
evaporated, and dried. To a solution of the reaction mixture in 3 mL of
DMF was added sodium azide (10 mg, 0.16 mmol). The reaction
mixture was stirred at 100 °C for 12 h and then concentrated. The
residue was dissolved in EtOAc, and the organic phase was evaporated
and dried. To a solution of residue in MeOH/CH2Cl2 (3/1, 3 mL) was
added 10% Pd/C (50 wt %). The reaction mixture was hydrogenated at
room temperature for 12 h. The catalyst was removed by ﬁltration
through a pad of Celite, which was rinsed with MeOH/CH2Cl2 (1/3).
The residue was washed with EtOAc/hexane (1/1), evaporated, and
dried, aﬀording RB-033 as a white solid. 1H NMR (400 MHz, CD3OD)
δ 0.89 (t, J = 6.9 Hz, 3H), 1.27−1.32 (m, 18H), 1.58−1.62 (m, 2H),
2.00−2.10 (m, 2H), 2.29 (d, J = 13.2, 2H), 2.58−2.62 (m, 2H), 3.05−
3.09 (m, 2H), 3.15 (d, J = 13.6 Hz, 2H), 3.28−3.33 (m, 2H), 3.46−3.54
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(m, 1H), 3.71 (d, J = 10.9 Hz, 2H), 7.17 (d, J = 7.9 Hz, 2H), 7.22 (d, J =
7.9 Hz, 2H); 13C NMR (100 MHz, CD3OD) δ 14.5, 23.8, 29.9, 30.3,
30.5, 30.6, 30.7, 30.8, 30.9, 31.3, 32.8, 33.1, 36.5, 36.9, 129.9, 130.1,
133.1, 143.1; ESI-HRMS (M + H)+ m/z calcd for C25H45N2 373.3583,
found 373.3576.
4-Fluoro-1-(4-octylphenethyl)piperidine (RB-034). To a sol-
ution of RB-005 (12 mg, 0.040 mmol) in CH2Cl2 (3 mL) at 0 °C was
added diethylaminosulfur triﬂuoride (DAST, 15 μL, 0.12 mmol). After
being stirred at room temperature for 5 h, the reaction mixture was
diluted with water, and the product was extracted with EtOAc. The
extract was washed with brine, evaporated, and dried. Puriﬁcation by
silica gel chromatography, eluting with CH2Cl2/MeOH (10:1), gave 11
mg (90%) of RB-034 as a colorless oil. 1H NMR (400 MHz, CDCl3) δ
0.87 (t, J = 6.8 Hz, 3H), 1.25−1.30 (m, 10H), 1.54−1.62 (m, 2H), 1.90−
2.00 (m, 4H), 2.48−2.63 (m, 6H), 2.66−2.71 (m, 2H), 2.76−2.80 (m,
2H), 4.61−4.66 (m, 0.5H), 4.74−4.78 (m, 0.5H), 7.10 (s, 4H); 13C
NMR (100 MHz, CDCl3) δ 14.1, 22.7, 29.3, 29.4, 29.5, 29.7, 33.2, 35.6,
49.4, 60.5, 128.5, 137.2, 140.8; ESI-HRMS (M + H)+ m/z calcd for
C21H35FN 320.2754, found 320.2751.
1-(4-Octylphenethyl)piperidin-4-one (RB-035).To a solution of
RB-005 (25 mg, 0.080 mmol) in CH2Cl2 (3 mL) at 0 °C was added
pyridinium chlorochromate (PCC, 25 mg, 0.12 mmol). After being
stirred at room temperature for 4 h, the reaction mixture was diluted
with water, and the product was extracted with EtOAc. The extract was
washed with brine, evaporated, and dried. Puriﬁcation by silica gel
chromatography, eluting with CH2Cl2/MeOH (3:1), gave 17 mg (70%)
of RB-035 as a colorless oil. 1H NMR (400 MHz, CDCl3) δ 0.87 (t, J =
6.6 Hz, 3H), 1.22−1.30 (m, 10H), 1.58−1.60 (m, 2H), 2.47−2.52 (m,
4H), 2.57 (t, J = 7.7 Hz, 2H), 2.72−2.74 (m, 2H), 2.81−2.86 (m, 6H),
7.12 (s, 4H); 13CNMR (100MHz, CDCl3) δ 14.1, 22.7, 29.3, 29.4, 29.5,
29.7, 31.6, 31.9, 33.7, 35.6, 36.0, 41.2, 53.1, 59.4, 128.6, 137.0, 141.0,
178.0; ESI-HRMS (M + H)+ m/z calcd for C21H34 NO 316.2640, found
316.2635.
4-Methoxy-1-(4-octylphenethyl)piperidine (RB-036). To a
solution of 117 (17 mg, 0.050 mmol) in MeCN (3 mL) was added 4-
methoxypiperidine (19 mg, 0.16 mmol). The reaction mixture was
stirred at 50 °C for 12 h. The solvent was evaporated and the residue was
puriﬁed by silica gel chromatography, eluting with CH2Cl2/MeOH
(5:1), to give 14 mg (79%) of RB-036 as a yellow liquid. 1H NMR (400
MHz, CDCl3) δ 0.87 (t, J = 6.5 Hz, 3H), 1.23−1.31 (m, 10H), 1.56−
1.61 (m, 2H), 1.67−1.72 (m, 2H), 1.95−2.00 (m, 2H), 2.30−2.37 (m,
2H), 2.56 (t, J = 7.7 Hz, 2H), 2.62−2.64 (m, 2H), 2.79−2.85 (m, 4H),
3.25−3.30 (m, 1H), 3.34 (s, 3H), 7.10 (s, 4H); 13C NMR (100 MHz,
CDCl3) δ 14.1, 22.7, 29.3, 29.4, 29.5, 31.6, 31.9, 35.6, 50.8, 55.6, 60.5,
128.5, 128.6, 140.8; ESI-HRMS (M + H)+ m/z calcd for C22H38NO
332.2953, found 332.2948.
(S)-1-(4-Octylphenethyl)pyrrolidin-3-ol (RB-037). To a solution
of 11 (20 mg, 0.064 mmol) inMeCN (4mL) was added K2CO3 (44mg,
0.32mmol) at room temperature. After the suspension was stirred for 10
min, (S)-pyrrolidine-3-ol hydrochloride (79 mg, 0.64 mmol) was added.
The reaction mixture was stirred at 50 °C for 12 h. The reaction mixture
was diluted with water, and the product was extracted with EtOAc. The
extract was washed with brine, dried, and evaporated. Puriﬁcation by
silica gel chromatography, eluting with CH2Cl2/MeOH (3:1), gave 17
mg (86%) of RB-037 as a yellow liquid. 1H NMR (400 MHz, CDCl3) δ
0.88 (t, J = 6.8 Hz, 3H), 1.22−1.32 (m, 10H), 1.58 (quin, J = 7.3 Hz,
2H), 1.85 (quin, J = 6.7 Hz, 1H), 2.19−2.28 (m, 1H), 2.46−2.54 (m,
2H), 2.56 (t, J = 7.8 Hz, 2H), 2.68 (dd, J = 5.1, 10.4 Hz, 1H), 2.78−2.88
(m, 4H), 2.91 (d, J = 10.4 Hz, 1H), 3.07−3.13 (m, 1H), 4.38−4.41 (m,
1H), 7.12 (s, 4H); 13C NMR (100MHz, CDCl3) δ 14.1, 22.7, 29.3, 29.4,
29.5, 31.6, 31.9, 34.3, 34.7, 35.6, 52.6, 57.8, 62.9, 71.1, 128.5, 128.6,
136.5, 141.0; ESI-HRMS (M + H)+ m/z calcd for C20H34NO 304.2640,
found 304.2639.
(R)-1-(4-Octylphenethyl)pyrrolidin-3-ol (RB-038). Compound
RB-038was prepared from 11 according to a coupling procedure similar
to that described for RB-036, using (R)-pyrrolidine. Yield = 72%; 1H
NMR (400 MHz, CDCl3) δ 0.88 (t, J = 6.7 Hz, 3H), 1.26−1.29 (m,
10H), 1.56−1.59 (m, 2H), 1.94−2.01 (m, 1H), 2.22−2.31 (m, 1H), 2.56
(t, J = 7.9 Hz, 2H), 2.74−2.76 (m, 1H), 2.91−2.99 (m, 4H), 3.14−3.24
(m, 2H), 3.30−3.35 (m, 1H), 4.47−4.50 (m, 1H), 7.12 (s, 4H); 13C
NMR (100 MHz, CDCl3) δ 14.1, 22.6, 29.3, 29.4, 29.5, 31.5, 31.9, 33.4,
34.2, 35.6, 52.9, 57.9, 62.7, 70.4, 128.5, 128.7, 135.2, 141.5; ESI-HRMS
(M + H)+ m/z calcd for C20H34NO 304.2640, found 304.2637.
(R)-(1-(4-Methylphenethyl)pyrrolidin-2-yl)methanol (RB-
039). Compound RB-039 was prepared from 2-(4-methylphenyl)-
ethanol according to a coupling procedure similar to that described for
RB-037, using D-prolinol. Yield = 62%; 1H NMR (400 MHz, CDCl3) δ
1.84−1.91 (m, 1H), 1.97−1.21 (m, 1H), 2.03−2.13 (m, 2H), 2.31 (s,
3H), 2.83−2.89 (m, 1H), 2.96−3.08 (m, 2H), 3.13−3.21 (m, 1H),
3.34−3.41 (m, 1H), 3.49−3.56 (m, 1H), 3.72−3.77 (m, 1H), 3.85 (d, J =
5.3 Hz, 2H), 7.12 (dd, J = 1.9, 8.4 Hz, 4H); 13C NMR (100 MHz,
CDCl3) δ 21.0, 23.6, 26.5, 32.0, 39.4, 50.7, 55.0, 57.9, 61.1, 69.5, 128.6,
129.5, 133.7, 136.7; ESI-HRMS (M + H)+ m/z calcd for C14H22NO
220.1701, found 220.1698.
(R)-(1-(4-Octylphenethyl)pyrrolidin-2-yl)methanol (RB-040).
Compound RB-040 was prepared from 11 according to a coupling
procedure similar to that described for RB-037, using D-prolinol. Yield =
59%; 1H NMR (400MHz, CDCl3) δ 0.88 (t, J = 6.8 Hz, 3H), 1.22−1.31
(m, 10H), 1.54−1.62 (m, 2H), 1.84−2.05 (m, 4H), 2.56 (t, J = 7.8 Hz,
2H), 2.64−2.70 (m, 1H), 2.85−3.00 (m, 3H), 3.08−3.13 (m, 1H),
3.32−3.36 (m, 1H), 3.57−3.62 (m, 1H), 3.67 (dd, J = 5.5, 13.7, Hz, 1H),
3.78 (dd, J = 3.2, 12.2 Hz, 1H), 7.11 (s, 4H); 13C NMR (100 MHz,
CDCl3) δ 14.1, 22.7, 23.8, 26.9, 29.3, 29.5, 29.7, 31.0, 31.5, 31.9, 35.6,
54.5, 56.9, 61.4, 66.3, 128.5, 128.7, 135.5, 141.5; ESI-HRMS (M + H)+
m/z calcd for C21H36NO 318.2797, found 318.2792.
(S)-(1-(4-Octylphenethyl)pyrrolidin-2-yl)methanol (RB-041).
Compound RB-041 was prepared from 11 according to a coupling
procedure similar to that described for RB-037, using L-prolinol. Yield =
54%; 1H NMR (400MHz, CDCl3) δ 0.88 (t, J = 6.7 Hz, 3H), 1.22−1.31
(m, 10H), 1.58 (quin, J = 7.3 Hz, 2H), 1.80−1.96 (m, 4H), 2.52−2.55
(m, 1H), 2.56 (t, J = 7.8 Hz, 2H), 2.73 (td, J = 11.6, 2.7 Hz, 1H), 2.86−
2.96 (m, 3H), 3.18−3.25 (m, 1H), 3.47 (quin, J = 4.7 Hz, 1H), 3.56 (dd,
J = 4.4, 11.7 Hz, 1H), 3.70 (dd, J = 3.2, 11.8 Hz, 1H), 7.11 (s, 4H); 13C
NMR (100 MHz, CDCl3) δ 14.1, 22.7, 23.8, 27.1, 29.3, 29.4, 29.5, 29.7,
31.5, 31.9, 33.7, 35.6, 54.3, 57.0, 61.5, 66.9, 128.5, 128.8, 135.8, 141.2;
ESI-HRMS (M + H)+ m/z calcd for C21H36NO 318.2797, found
318.2791.
(R)-(1-(4-Dodecylphenethyl)pyrrolidin-2-yl)methanol (RB-
042). Compound RB-042 was prepared from 9 according to a coupling
procedure similar to that described for RB-037, using D-prolinol. Yield =
62%; 1H NMR (400MHz, CDCl3) δ 0.87 (t, J = 6.6 Hz, 3H), 1.22−1.31
(m, 18H), 1.56−1.60 (m, 2H), 2.00−2.16 (m, 4H), 2.56 (t, J = 7.7 Hz,
2H), 2.82−2.88 (m, 1H), 3.03−3.09 (m, 2H), 3.22−3.30 (m, 1H),
3.35−3.39 (m, 1H), 3.46−3.53 (m, 1H), 3.75−3.80 (m, 1H), 3.86 (dd, J
= 6.5, 12.7 Hz, 1H), 3.95 (dd, J = 2.1, 12.0 Hz, 1H), 7.12 (s, 4H); 13C
NMR (100 MHz, CDCl3) δ 14.1, 22.7, 24.0, 26.5, 29.3, 29.4, 29.5, 29.6,
29.7, 31.5, 31.8, 31.9, 35.5, 54.7, 58.0, 60.9, 70.2, 128.5, 128.9, 133.6,
142.0; ESI-HRMS (M + H)+ m/z calcd for C25H44NO 374.3423, found
374.3418.
(S)-(1-(4-Dodecylphenethyl)pyrrolidin-2-yl)methanol (RB-
043). Compound RB-043 was prepared from 9 according to a coupling
procedure similar to that described for RB-037, using L-prolinol. Yield =
55%; 1H NMR (400MHz, CDCl3) δ 0.88 (t, J = 6.6 Hz, 3H), 1.23−1.30
(m, 18H), 1.56−1.62 (m, 2H), 1.93−2.11 (m, 4H), 2.56 (t, J = 7.8 Hz,
2H), 2.98−3.06 (m, 2H), 3.14−3.22 (m, 1H), 3.28−3.32 (m, 1H),
3.41−3.49 (m, 1H), 3.65−3.68 (m, 1H), 3.71−3.73 (m, 1H), 3.79−3.83
(m, 1H), 3.89 (dd, J = 2.5, 12.0 Hz, 1H), 7.12 (s, 4H); 13C NMR (100
MHz, CDCl3) δ 14.1, 22.7, 23.9, 26.8, 29.4, 29.5, 29.6, 29.7, 31.5, 31.9,
35.6, 54.5, 57.5, 61.1, 70.1, 128.5, 128.8, 134.1, 141.7; ESI-HRMS (M +
H)+ m/z calcd for C25H44NO 374.3423, found 374.3415.
4-(Oct-1-ynyl)benzoic Acid (12). To a deaerated solution of 4-
iodobenzoic acid (500 mg, 2.02 mmol), bis(triphenylphosphine)-
palladium dichloride (116 mg, 0.10 mmol), and copper(I) iodide (19
mg, 0.10 mmol) in anhydrous triethylamine (15 mL) was added 1-
octyne (0.89 mL, 6.05 mmol) at room temperature. The reaction
mixture was heated at 60 °C for 12 h. After saturated aqueous
ammonium chloride solution was added, the product was extracted with
EtOAc. The combined solution was washed with water, brine, and dried.
Puriﬁcation by silica gel chromatography, eluting with hexane/EtOAc
(3:1), gave 395 mg (85%) of alkyne 12 as a yellow liquid. 1H NMR (400
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MHz, CDCl3) δ 0.90 (t, J = 6.7 Hz, 3H), 1.31−1.35 (m, 4H), 1.43−1.50
(m, 2H), 1.58−1.66 (m, 2H), 2.43 (t, J = 7.1Hz, 2H), 7.47 (d, J = 8.4Hz,
2H), 8.02 (d, J = 8.4Hz, 2H); 13CNMR (100MHz, CDCl3) δ 13.8, 19.3,
22.3, 28.3, 31.1, 79.8, 94.4, 127.6, 129.6, 129.7, 131.3, 171.8; ESI-HRMS
(M − H)− m/z calcd for C15H17O2− 229.1234, found 229.1237.
4-Octylbenzoic Acid (13). Compound 12 (300 mg, 1.30 mmol)
was dissolved in EtOAc (10 mL), and 10% Pd/C (150 mg, 50 wt %) was
added. The reaction mixture was hydrogenated at room temperature for
12 h. The catalyst was removed by ﬁltration through a pad of Celite,
which was rinsed with EtOAc, aﬀording 13 as a yellow solid without
puriﬁcation. 1H NMR (400 MHz, CDCl3) δ 0.88 (t, J = 6.8 Hz, 3H),
1.22−1.32 (m, 10H), 1.61−1.64 (m, 2H), 2.64 (t, J = 7.7 Hz, 2H), 7.25
(d, J = 8.1 Hz, 2H), 8.02 (d, J = 8.2 Hz, 2H); 13C NMR (100 MHz,
CDCl3) δ 14.1, 22.7, 29.3, 29.4, 31.1, 31.9, 36.1, 126.9, 128.6, 130.3,
149.6, 172.6; ESI-HRMS (M−H)− m/z calcd for C15H21O2− 233.1547,
found 233.1548.
(R)-(4-Dodecylphenyl)-(2-(hydroxymethyl)pyrrolidin-1-yl)-
methanone (RB-044). To a solution of 4-(n-dodecyl)benzoic acid (10
mg, 0.034 mmol) in CH2Cl2 (3 mL) was added thionyl chloride (0.25
mL, 0.34 mmol) at room temperature. The reaction mixture was heated
at reﬂux for 12 h. The reaction mixture was diluted with water, and the
product was extracted with EtOAc. The extract was washed with brine,
dried, and evaporated. To a solution of residue in MeCN (3 mL) was
added K2CO3 (24 mg, 0.17 mmol) at room temperature. After the
suspension was stirred for 10 min, D-prolinol (10 mg, 0.10 mmol) was
added. The reaction mixture was stirred at 50 °C for 12 h. The reaction
mixture was diluted with water, and the product was extracted with
EtOAc. The extract was washed with brine, dried, and evaporated.
Puriﬁcation by silica gel chromatography, eluting with CH2Cl2/MeOH
(10:1), gave 9 mg (72%) of RB-044 as a yellow liquid. 1H NMR (400
MHz, CDCl3) δ 0.88 (t, J = 6.6 Hz, 3H), 1.23−1.34 (m, 18H), 1.59−
1.64 (m, 4H), 1.70−1.77 (m, 1H), 1.84−1.89 (m, 1H), 2.14−2.21 (m,
1H), 2.62 (t, J = 7.6 Hz, 2H), 3.46−3.59 (m, 2H), 3.71−3.82 (m, 2H),
4.39−4.44 (m, 1H), 7.20 (d, J = 7.9 Hz, 2H), 7.43 (d, J = 7.9 Hz, 2H);
13C NMR (100 MHz, CDCl3) δ 14.1, 22.7, 25.1, 28.6, 29.2, 29.3, 29.4,
29.5, 29.6, 29.7, 31.3, 31.9, 35.8, 51.3, 61.6, 67.6, 127.2, 128.3, 133.8,
145.5, 172.5; ESI-HRMS (M +H)+m/z calcd for C24H40NO2 374.3059,
found 374.3055.
(S)-(4-Dodecylphenyl)(2-(hydroxymethyl)pyrrolidin-1-yl)-
methanone (RB-045). Compound RB-045 was prepared from 4-(n-
dodecyl)benzoic acid according to a coupling procedure similar to that
described for RB-044, using L-prolinol instead of D-prolinol. Yield =
65%; 1HNMR (400MHz, CDCl3) δ 0.88 (t, J = 6.7 Hz, 3H), 1.23−1.30
(m, 18H), 1.58−1.64 (m, 4H), 1.70−1.77 (m, 1H), 1.84−1.89 (m, 1H),
2.14−2.21 (m, 1H), 2.62 (t, J = 7.7 Hz, 2H), 3.47−3.59 (m, 2H), 3.71−
3.82 (m, 2H), 4.38−4.44 (m, 1H), 7.20 (d, J = 8.0 Hz, 2H), 7.43 (d, J =
7.9 Hz, 2H); 13C NMR (100MHz, CDCl3) δ 14.1, 22.7, 25.1, 28.6, 29.2,
29.4, 29.5, 29.6, 29.7, 31.2, 31.9, 35.8, 51.3, 61.6, 67.5, 127.2, 128.3,
133.8, 145.5, 172.5; ESI-HRMS (M + H)+ m/z calcd for C24H40NO2
374.3059, found 374.3058.
(4-Hydroxypiperidin-1-yl)(4-octylphenyl)methanone (RB-
046). Compound RB-046 was prepared from 4-(n-dodecyl)benzoic
acid according to a coupling procedure similar to that described for RB-
044, using 4-hydroxypiperidine. Yield = 70%; 1H NMR (400 MHz,
CDCl3) δ 0.88 (t, J = 6.7 Hz, 3H), 1.26−1.30 (m, 10H), 1.51−1.62 (m,
4H), 1.80−1.97 (m, 2H), 2.63 (t, J = 7.7 Hz, 2H), 3.21−3.36 (m, 2H),
3.67−3.76 (m, 1H), 3.93−4.00 (m, 1H), 4.18−4.26 (m, 1H), 7.19 (d, J =
8.2 Hz, 2H), 7.31 (d, J = 8.2 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ
14.1, 22.7, 29.2, 29.3, 29.4, 31.3, 35.8, 67.4, 126.9, 128.5, 130.2, 133.2,
144.8, 170.7; ESI-HRMS (M +H)+m/z calcd for C20H32NO2 318.2428,
found 318.2432.
(4-Dodecylphenyl)(4-hydroxypiperidin-1-yl)methanone (RB-
047). Compound RB-047 was prepared from 4-(n-dodecyl)benzoic
acid according to a coupling procedure similar to that described for RB-
044, using 4-hydroxypiperidine. Yield = 81%; 1H NMR (400 MHz,
CDCl3) δ 0.88 (t, J = 6.7 Hz, 3H), 1.22−1.37 (m, 18H), 1.58−1.63 (m,
4H), 1.84−1.95 (m, 2H), 2.61 (t, J = 7.7 Hz, 2H), 3.21−3.34 (m, 2H),
3.67−3.75 (m, 1H), 3.95 (sep, J = 3.9 Hz, 1H), 4.18−4.23 (m, 1H), 7.19
(d, J = 7.9 Hz, 2H), 7.30 (d, J = 8.0 Hz, 2H); 13C NMR (100 MHz,
CDCl3) δ 14.2, 22.7, 29.3, 29.4, 29.5, 29.6, 29.7, 31.3, 31.9, 35.8, 67.2,
126.9, 128.5, 133.1, 144.9, 170.8; ESI-HRMS (M + H)+ m/z calcd for
C24H40NO2 374.3059, found 374.3055.
4-Octyl-N-(pyridin-4-ylmethyl)benzamide (RB-048). Com-
pound RB-048 was prepared from 4-(n-dodecyl)benzoic acid according
to a coupling procedure similar to that described for RB-044, using 4-
(aminomethyl)pyridine. Yield = 69%; 1H NMR (400 MHz, CDCl3) δ
0.88 (t, J = 6.8 Hz, 3H), 1.07−1.30 (m, 10H), 1.59−1.63 (m, 2H), 2.65
(t, J = 7.7 Hz, 2H), 4.63 (d, J = 6.0Hz, 2H), 6.97 (t, J = 5.6Hz, NH), 7.24
(d, J = 8.0 Hz, 4H), 7.74 (d, J = 8.2 Hz, 2H), 8.51−8.56 (m, 2H); 13C
NMR (100 MHz, CDCl3) δ 14.1, 21.1, 22.7, 29.2, 29.4, 29.7, 31.2, 31.8,
35.8, 42.7, 60.4, 127.1, 128.5, 128.7, 131.2, 147.4, 147.8, 149.9, 167.7,
171.2; ESI-HRMS (M +H)+m/z calcd for C21H29N2O 325.2274, found
325.2277.
N-(4-Hydroxyphenyl)-4-octylbenzamide (RB-049). Compound
RB-049 was prepared from 4-(n-dodecyl)benzoic acid according to a
coupling procedure similar to that described for RB-044, using 4-
aminophenol. Yield = 55%; 1H NMR (400 MHz, CDCl3) δ 0.88 (t, J =
6.8 Hz, 3H), 1.11−1.29 (m, 10H), 1.54−1.60 (m, 2H), 2.67 (t, J = 7.1
Hz, 2H), 6.83 (d, J = 7.8 Hz, 2H), 7.28 (d, J = 7.8 Hz, 2H), 7.43 (d, J =
6.8 Hz, 2H), 7.80 (d, J = 6.8 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ
14.3, 22.9, 27.6, 29.6, 29.7, 30.0, 30.4, 31.6, 32.2, 36.2, 123.2, 127.5,
129.0, 132.5, 147.6, 167.8; ESI-HRMS (M + H)+ m/z calcd for
C21H28NO2 326.2115, found 326.2118.
N-(4-(2-Hydroxyethyl)phenyl)-4-octylbenzamide (RB-050).
Compound RB-050 was prepared from 4-(n-dodecyl)benzoic acid
according to a coupling procedure similar to that described for RB-044,
using 2-(4-aminophenyl)ethanol. Yield = 73%; 1H NMR (400 MHz,
CDCl3) δ 0.88 (t, J = 6.8 Hz, 3H), 1.24−1.32 (m, 10H), 1.51−1.60 (m,
2H), 2.67 (t, J = 7.7 Hz, 2H), 2.87 (t, J = 6.5 Hz, 2H), 3.86 (t, J = 6.5 Hz,
2H), 7.23 (d, J = 8.4 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 7.58 (d, J = 8.4
Hz, 2H), 7.76 (br s, NH), 7.78 (d, J = 8.1 Hz, 2H); 13CNMR (100MHz,
CDCl3) δ 14.1, 22.7, 27.3, 29.2, 29.4, 29.7, 31.2, 31.9, 38.6, 63.7, 120.5,
127.0, 128.9, 129.7, 132.3, 134.6, 136.5, 147.4, 165.7; ESI-HRMS (M +
Na)+ m/z calcd for C23H31NO2Na 376.2247, found 376.2251.
1-Bromo-4-(oct-1-ynyl)benzene (14). Compound 14 was
prepared from 1-bromo-4-iodobenzene according to a procedure
similar to that described for 1. Yield = 70%; 1H NMR (400 MHz,
CDCl3) δ 0.90 (t, J = 7.1 Hz, 3H), 1.29−1.34 (m, 4H), 1.40−1.47 (m,
2H), 1.59 (quin, J = 7.3 Hz, 2H), 2.37 (t, J = 7.1 Hz, 2H), 7.24 (dt, J =
8.3, 2.0 Hz, 2H), 7.39 (dt, J = 8.6, 2.0 Hz, 2H); 13C NMR (100 MHz,
CDCl3) δ 14.1, 19.5, 22.6, 28.8, 31.4, 79.6, 91.8, 121.5, 123.1, 131.4,
133.0; ESI-HRMS (M)+ m/z calcd for C14H17Br 264.0514, found
264.0508.
4-(4-Octylphenethyl)pyridine (RB-051). To a deaerated solution
of 14 (100 mg, 0.38 mmol), bis(triphenylphosphine)palladium
dichloride (22 mg, 0.010 mmol), and copper(I) iodide (4 mg, 10
μmol) in anhydrous triethylamine (8 mL) was added 3-ethynylpyridine
(78 mg, 0.75 mmol) at room temperature. The reaction mixture was
heated at 80 °C for 3 days. After saturated ammonium chloride solution
was added, the product was extracted with EtOAc. The combined
solution was washed with water, brine and dried. The catalyst was
removed by ﬁltration through a pad of Celite, which was rinsed with
hexanes/EtOAc (3:1). 3-((4-(Oct-1-ynyl)phenyl)ethynyl)pyridine
(15) (53 mg, 0.18 mmol) was dissolved in EtOAc (8 mL), and 10%
Pd/C (53 mg, 100 wt %) was added. The reaction mixture was
hydrogenated at room temperature for 12 h. The catalyst was removed
by ﬁltration through a pad of Celite, which was rinsed with EtOAc. Flash
column chromatography with hexanes/EtOAc (1:1) as eluent gave RB-
051 (48mg, 88%) as a yellow oil. 1HNMR (400MHz, CDCl3) δ 0.88 (t,
J = 6.8 Hz, 3H), 1.27−1.34 (m, 10H), 1.59 (quin, J = 7.3 Hz, 2H), 2.56
(t, J = 7.8 Hz, 2H), 2.86−2.92 (m, 4H), 7.05 (d, J = 8.1 Hz, 2H), 7.09 (d,
J = 8.1 Hz, 2H), 7.17 (dd, J = 4.8, 7.7 Hz, 1H), 7.43 (dt, J = 7.8, 1.8 Hz,
1H), 8.42−8.44 (m, 2H); 13C NMR (100 MHz, CDCl3) δ 14.2, 22.7,
29.3, 29.4, 29.5, 31.6, 31.9, 35.0, 35.6, 37.1, 123.2, 128.3, 128.5, 135.9,
137.0, 140.8, 147.5, 150.0; ESI-HRMS (M +H)+m/z calcd for C21H30N
296.2378, found 296.2374.
1-Methyl-4-(4-octylphenethyl)pyridinium Iodide (RB-052).
To a solution of RB-051 (32 mg, 0.11 mmol) in MeCN (5 mL) was
added K2CO3 (75 mg, 0.54 mmol). After the suspension was stirred at
room temperature for 10 min, MeI (30 μL, 0.54 mmol) was added. The
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reaction mixture was stirred overnight at room temperature. The
reaction mixture was diluted with water, and the product was extracted
with EtOAc. The extract was washed with brine, dried, and evaporated.
The residue was washed with hexane to give 38 mg (80%) of RB-052 as
a yellow solid. 1H NMR (400 MHz, CDCl3) δ 0.88 (t, J = 6.9 Hz, 3H),
1.26−1.30 (m, 10H), 1.56 (quin, J = 7.3 Hz, 2H), 2.54 (t, J = 7.8 Hz,
2H), 3.02 (t, J = 7.6 Hz, 2H), 3.17 (t, J = 7.6 Hz, 2H), 4.60 (s, 3H), 7.07
(s, 4H), 7.92 (dd, J = 6.2, 7.7 Hz, 1H), 8.06 (d, J = 8.0 Hz, 1H), 9.12 (d, J
= 6.5 Hz, 2H); 13C NMR (100 MHz, CDCl3) δ 14.1, 22.7, 29.3, 29.4,
29.5, 31.6, 31.9, 34.4, 35.5, 35.7, 49.2, 127.6, 128.6, 128.7, 136.1, 141.4,
142.8, 143.0, 145.1, 145.2; ESI-HRMS (M)+ m/z calcd for C22H32N
+
310.2535, found 310.2533.
1-(Bromomethyl)-4-(oct-1-ynyl)benzene (16). Compound 16
was prepared from 4-iodobenzyl bromide according to a procedure
similar to that described for 1. Yield = 69%; 1H NMR (400 MHz,
CDCl3) δ 0.87 (t, J = 6.9 Hz, 3H), 1.27−1.30 (m, 8H), 2.38 (t, J = 6.8
Hz, 2H), 4.44 (s, 2H), 7.30 (d, J = 8.0 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H);
13C NMR (100 MHz, CDCl3) δ 14.1, 19.3, 22.4, 28.4, 28.7, 31.2, 33.3,
80.0, 91.2, 124.3, 128.9, 131.8, 136.9; ESI-HRMS (M + H)+ m/z calcd
for C15H20Br 279.0748, found 279.0730.
4-(4-Methylpiperidin-1-yl)-1-(4-(oct-1-ynyl)benzyl)-
pyridinium Bromide (18).27 To a Pyrex vessel charged with a
magnetic stirring bar was added a suspension of 4-chloropyridine
hydrochloride (0.20 g, 1.3 mmol) in dry acetonitrile (4 mL). N,N-
Diisopropylethylamine (DIPEA, 0.7 mL, 4.0 mmol) was added,
followed by 4-methylpiperidine (0.16 mL, 1.3 mmol). The reactor
was placed in a microwave apparatus and irradiated at 160 °C for 1 h.
After the reaction mixture was cooled to room temperature, EtOAc was
added, and the solution was washed with water and brine, dried
(Na2SO4), and concentrated in vacuo. Ether (3 mL) was added to the
resulting crude oil, and the inorganic precipitate was removed by
ﬁltration. Evaporation of the solvent gave 4-(4-methylpiperidin-1-
yl)pyridine (17). A solution of 16 (100mg, 0.35mmol) and 17 (124mg,
0.71 mmol) in 5 mL of 2-butanone was placed in a sealed tube. The
reaction mixture was stirred at 100 °C for 3 days and concentrated. The
residue was washed with EtOAc to give 125 mg (78%) of 18 as a slightly
yellow solid. 1H NMR (400 MHz, CDCl3) δ 0.90 (t, J = 6.9 Hz, 3H),
0.98 (d, J = 6.4 Hz, 3H), 1.15−1.32 (m, 6H), 1.40−1.47 (m, 2H), 1.59
(quin, J = 7.28 Hz, 2H), 1.74−1.79 (m, 1H), 1.84 (d, J = 13.2 Hz, 2H),
2.39 (t, J = 7.1 Hz, 2H), 3.12 (td, J = 12.9, 2.1 Hz, 2H), 4.04 (d, J = 13.4
Hz, 2H), 5.60 (s, 2H), 6.95 (d, J = 7.1 Hz, 2H), 7.36 (d, J = 8.1 Hz, 2H),
7.43 (d, J = 8.1 Hz, 2H), 8.56 (d, J = 7.1 Hz, 2H); 13C NMR (100 MHz,
CDCl3) δ 14.2, 19.4, 21.3, 22.6, 28.6, 29.7, 30.5, 31.3, 33.5, 47.4, 60.3,
79.8, 92.2, 108.4, 125.3, 128.9, 132.4, 133.1, 143.0, 155.2; ESI-HRMS
(M + H)+ m/z calcd for C26H36N2
+ 376.2873, found 376.2871.
4-(4-Methylpiperidin-1-yl)-1-(4-octylbenzyl)pyridinium Bro-
mide (RB-053). Compound 18 (10 mg, 0.02 mmol) was dissolved in
MeOH/CH2Cl2 (1/3, 3 mL), and 10% Pd/C (10 mg, 100 wt %) was
added. The reaction mixture was hydrogenated at room temperature for
12 h. The catalyst was removed by ﬁltration through a pad of Celite,
which was rinsed with CH2Cl2 and concentrated. The residue was
washed with hexane to give 9 mg (87%) of RB-053 as a white solid. 1H
NMR (400 MHz, CDCl3) δ 0.86 (t, J = 7.0 Hz, 3H), 0.98 (d, J = 6.4 Hz,
3H), 1.16−1.33 (m, 10H), 1.55−1.60 (m, 4H), 1.72−1.78 (m, 1H), 1.84
(d, J = 13.8 Hz, 2H), 2.58 (d, J = 7.6 Hz, 2H), 3.13 (td, J = 12.5, 2.4 Hz,
2H), 4.08 (d, J = 13.5 Hz, 2H), 5.47 (s, 2H), 7.02 (d, J = 7.6 Hz, 2H),
7.18 (d, J = 8.0 Hz, 2H), 7.34 (d, J = 8.0 Hz, 2H), 8.46 (d, J = 7.6 Hz,
2H); 13C NMR (100 MHz, CDCl3) δ 14.1, 21.3, 22.7, 29.2, 29.3, 29.4,
29.7, 30.3, 30.5, 31.4, 31.9, 33.5, 35.7, 47.5, 60.8, 108.5, 128.8, 129.5,
130.9, 142.8, 144.5, 155.2; ESI-HRMS (M)+ m/z calcd for C26H39N2
+
379.3113, found 379.3108.
4-(Oct-1-ynyl)aniline (19). Compound 19 was prepared from 4-
iodoaniline according to a procedure similar to that described for 1.
Yield = 62%; 1H NMR (400 MHz, CDCl3) δ 0.90 (t, J = 7.0 Hz, 3H),
1.26−1.35 (m, 4H), 1.40−1.47 (m, 2H), 1.58 (quin, J = 7.4 Hz, 2H),
2.37 (t, J = 7.1Hz, 2H), 6.57 (d, J = 8.6Hz, 2H), 7.19 (d, J = 8.6 Hz, 2H);
13C NMR (100 MHz, CDCl3) δ 14.1, 19.5, 22.6, 28.6, 29.0, 31.4, 80.7,
87.9, 113.7, 114.8, 132.7, 145.9; ESI-HRMS (M + H)+ m/z calcd for
C14H20N 202.1596, found 202.1589.
3-(1-(4-(Oct-1-ynyl)phenyl)-1H-1,2,3-triazol-4-yl)pyridine
(21).28 To a solution of 19 (157 mg, 0.78 mmol) in 2 mL of 10%
aqueous HCl was addedNaNO2 (65mg, 0.94mmol) in 1mL of water at
0 °C. After the solution was stirred for 30 min, NaN3 (61 mg, 0.94
mmol) in 1 mL of water was added at 0 °C, with stirring for another
hour. The reaction mixture was warmed to 25 °C, diluted with EtOAc,
washed with water and brine, dried (Na2SO4), and concentrated in
vacuo, aﬀording 20. Without puriﬁcation, 20 (43 mg, 0.19 mmol) and 3-
ethynylpyridine (39 mg, 0.38 mmol) were dissolved in t-BuOH/H2O (3
mL, 1:1), and CuSO4 (30 mg, 0.19 mmol) and sodium ascorbate (37
mg, 0.19 mmol) were added at room temperature. The reaction mixture
was stirred for 2 days and then was diluted with EtOAc and washed with
brine. The aqueous layer was extracted with EtOAc. The combined
organic layers were dried (MgSO4) and concentrated in vacuo.
Puriﬁcation by silica gel chromatography, eluting with hexanes/EtOAc
(1:1), gave 50 mg (67%, two steps) of 21 as a white solid. 1HNMR (400
MHz, CDCl3) δ 0.92 (t, J = 6.9 Hz, 3H), 1.29−1.38 (m, 4H), 1.47 (quin,
J = 7.3 Hz, 2H), 1.63 (quin, J = 7.3 Hz, 2H), 2.44 (t, J = 7.1 Hz, 2H), 7.41
(dd, J = 4.8, 7.9 Hz, 1H), 7.57 (d, J = 8.6 Hz, 2H), 7.74 (d, J = 8.6 Hz,
2H), 8.27−8.30 (m, 2H), 8.61−8.63 (m, 1H), 9.08 (s, 1H); 13C NMR
(100 MHz, CDCl3) δ 14.1, 19.5, 22.6, 28.5, 28.6, 31.4, 79.3, 93.0, 117.8,
120.2, 123.1, 123.9, 125.2, 126.4, 133.0, 133.3, 135.6, 139.5, 145.4, 147.1,
149.6, 153.2, ESI-HRMS (M + H)+ m/z calcd for C21H23N4 331.1923,
found 331.1919.
3-(1-(4-Octylphenyl)-1H-1,2,3-triazol-4-yl)pyridine (RB-054).
Compound RB-054 was prepared from 21 according to a procedure
similar to that described for 2. Yield = 82%; 1H NMR (400 MHz,
CDCl3) δ 0.89 (t, J = 6.8 Hz, 3H), 1.25−1.35 (m, 10H), 1.62−1.68 (m,
2H), 2.69 (t, J = 7.7 Hz, 2H), 7.36 (d, J = 8.3 Hz, 2H), 7.42 (dd, J = 4.8,
7.8 Hz, 1H), 7.69 (d, J = 8.3 Hz, 2H), 8.25 (s, 1H), 8.30 (d, J = 7.9 Hz,
1H), 8.61−8.63 (m, 1H), 9.08 (s, 1H); 13C NMR (100 MHz, CDCl3) δ
14.1, 22.7, 29.2, 29.3, 29.4, 29.7, 31.4, 31.9, 35.5, 118.1, 120.6, 123.9,
126.6, 129.8, 133.2, 134.7, 144.4, 145.2, 147.1, 149.4; ESI-HRMS (M +
H)+ m/z calcd for C21H27N4 335.2236, found 335.2232.
4-(4-Octyl-1H-1,2,3-triazol-1-yl)phenol (RB-055). To a solution
of 4-aminophenol (100 mg, 0.92 mmol) in 2 mL of 10% aqueous HCl
was added NaNO2 (76 mg, 1.10 mmol) in 1 mL of water at 0 °C. After
the solution was stirred for 30 min, NaN3 (72mg, 1.10 mmol) in 1mL of
water was added at 0 °C, with stirring for another hour. The reaction
mixture was warmed to 25 °C, diluted with EtOAc, washed with water
and brine, dried (Na2SO4), and concentrated in vacuo, aﬀording 4-
azidophenol (22). Without puriﬁcation, 22 (20 mg, 0.15 mmol) and 1-
decyne (61 mg, 0.44 mmol) were dissolved in t-BuOH/H2O (5 mL,
1:1), and CuSO4 (35 mg, 0.22 mmol) and sodium ascorbate (44 mg,
0.22 mmol) were added at room temperature. The reaction mixture was
stirred for 2 days and then was diluted with EtOAc and washed with
brine. The aqueous layer was extracted with EtOAc. The combined
organic layers were dried (MgSO4) and concentrated in vacuo.
Puriﬁcation by silica gel chromatography, eluting with CH2Cl2/
MeOH (10:1), gave 26 mg (70%, two steps) of RB-055 as a white
solid. 1HNMR (400MHz, CDCl3) δ 0.86 (t, J = 6.7 Hz, 3H), 1.23−1.38
(m, 10H), 1.72 (t, J = 8.6 Hz, 2H), 2.79 (t, J = 8.5 Hz, 2H), 7.11 (d, J =
7.6 Hz, 2H), 7.54 (d, J = 7.6 Hz, 2H), 7.68 (s, 1H); 13CNMR (100MHz,
CDCl3) δ 14.1, 22.6, 25.5, 29.2, 29.3, 29.4, 31.8, 116.7, 119.6, 122.3,
129.7, 148.8, 157.7; ESI-HRMS (M + H)+ m/z calcd for C16H24N3O
274.1914, found 274.1918.
2-(4-(4-Octyl-1H-1,2,3-triazol-1-yl)phenyl)ethanol (RB-056).
To a solution of 2326 (200 mg, 1.23 mmol) and 1-decyne (508 mg,
3.68 mmol) in t-BuOH/H2O (6 mL, 1:1) were added CuSO4 (196 mg,
1.23 mmol) and sodium ascorbate (243 mg, 1.23 mmol). The reaction
mixture was stirred at room temperature for 12 h and then was diluted
with EtOAc and washed with brine. The aqueous layer was extracted
with EtOAc. The combined organic layers were dried (MgSO4) and
concentrated in vacuo. Puriﬁcation by silica gel chromatography, eluting
with CH2Cl2/MeOH (10:1), gave 296 mg (80%) of RB-056 as a white
solid. 1HNMR (400MHz, CDCl3) δ 0.88 (t, J = 6.9 Hz, 3H), 1.27−1.42
(m, 10H), 1.71 (quin, J = 7.5 Hz, 2H), 2.76 (t, J = 7.7 Hz, 2H), 2.92 (t, J
= 6.6 Hz, 2H), 3.89 (t, J = 6.6 Hz, 2H), 7.35 (d, J = 8.5 Hz, 2H), 7.61 (d, J
= 8.5 Hz, 2H), 7.70 (s, 1H); 13C NMR (100 MHz, CDCl3) δ 14.1, 22.6,
25.6, 29.1, 29.2, 29.3, 29.4, 31.8, 38.7, 63.1, 118.9, 120.4, 130.2, 135.6,
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139.7, 149.1; ESI-HRMS (M +H)+m/z calcd for C18H28N3O 302.2227,
found 302.2230.
4-(4-Butyl-1H-1,2,3-triazol-1-yl)phenethylMethanesulfonate
(26). To a solution of 2326 (200 mg, 1.23 mmol) and 1-hexyne (0.42
mL, 3.68 mmol) in tert-BuOH/H2O (6 mL, 1:1) were added CuSO4
(196 mg, 1.23 mmol) and sodium ascorbate (243 mg, 1.23 mmol). The
reaction mixture was stirred at room temperature for 12 h and then was
diluted with EtOAc and washed with brine. The aqueous layer was
extracted with EtOAc. The combined organic layers were dried
(MgSO4) and concentrated in vacuo. Compound 24 was obtained,
without puriﬁcation, as a yellow liquid. To a solution of 24 (1.23 mmol)
and triethylamine (0.86 mL, 6.15 mmol) in CH2Cl2 (10 mL) at 0 °Cwas
added methanesulfonyl chloride (0.29 mL, 3.69 mmol). After being
stirred at room temperature for 5 h, the reactionmixture was evaporated,
diluted with water, and the product was extracted with EtOAc. The
extract was washed with brine, dried, and evaporated. Puriﬁcation by
silica gel chromatography, eluting with hexanes/EtOAc (1:2), gave 253
mg (66%, two steps) of 26 as a white solid. 1HNMR (400MHz, CDCl3)
δ 0.96 (t, J = 7.3 Hz, 3H), 1.43 (sex, J = 7.5 Hz, 2H), 1.72 (quin, J = 7.6
Hz, 2H), 2.80 (t, J = 7.7 Hz, 2H), 2.92 (s, 3H), 3.12 (t, J = 6.7 Hz, 2H),
4.45 (t, J = 6.7 Hz, 2H), 7.38 (d, J = 8.5 Hz, 2H), 7.69 (d, J = 8.5 Hz, 2H),
7.73 (s, 1H); 13CNMR (100MHz, CDCl3) δ 13.9, 22.3, 25.3, 31.5, 31.6,
35.1, 37.4, 69.7, 118.8, 120.6, 130.3, 136.3, 136.9, 149.2; ESI-HRMS (M
+ H)+ m/z calcd for C15H22N3O3S 324.1382, found 324.1382.
4-(4-Pentyl-1H-1,2,3-triazol-1-yl)phenethyl Methanesulfo-
nate (27). Compound 27 was prepared from 23, via 25, according to
a coupling procedure similar to that described for 26, using 1-heptyne.
Yield = 58% (two steps); 1H NMR (400 MHz, CDCl3) δ 0.91 (t, J = 7.1
Hz, 3H), 1.36−1.40 (m, 4H), 1.74 (quin, J = 7.5 Hz, 2H), 2.79 (t, J = 7.7
Hz, 2H), 2.93 (s, 3H), 3.12 (t, J = 6.7 Hz, 2H), 4.46 (t, J = 6.7 Hz, 2H),
7.38 (d, J = 8.5 Hz, 2H), 7.69 (d, J = 8.5 Hz, 2H), 7.74 (s, 1H); 13CNMR
(100 MHz, CDCl3) δ 14.0, 22.4, 25.6, 29.1, 31.4, 31.6, 35.1, 37.4, 60.4,
69.7, 118.8, 120.6, 130.3, 136.2, 136.9, 149.3; ESI-HRMS (M +H)+m/z
calcd for C16H24N3O3S 338.1538, found 338.1536.
1-(4-(4-Butyl-1H-1,2,3-triazol-1-yl)phenethyl)piperidine (RB-
057). To a solution of 26 (50 mg, 0.15 mmol) in 3 mL of acetonitrile
was added piperidine (150 μL, 1.54 mmol). The reaction mixture was
stirred at 50 °C for 12 h and concentrated. Puriﬁcation by silica gel
chromatography, eluting with CH2Cl2/MeOH (5:1), gave 11 mg (75%)
ofRB-057 as a slightly yellowwaxy solid. 1HNMR (400MHz, CDCl3) δ
0.96 (t, J = 7.4 Hz, 3H), 1.42 (sex, J = 7.4 Hz, 2H), 1.51−1.55 (m, 2H),
1.72 (quin, J = 7.6 Hz, 2H), 1.80 (quin, J = 5.4 Hz, 4H), 2.74−2.83 (m,
8H), 3.04−3.08 (m, 2H), 7.36 (d, J = 8.4 Hz, 2H), 7.63 (d, J = 8.4 Hz,
2H), 7.71 (s, 1H); 13C NMR (100MHz, CDCl3) δ 13.9, 22.3, 23.5, 24.7,
25.3, 29.7, 31.5, 31.9, 54.1, 60.0, 118.8, 120.5, 130.0, 135.7, 139.6, 149.1;
ESI-HRMS (M + H)+ m/z calcd for C19H29N4 313.2392, found
313.2385.
1-(4-(4-Pentyl-1H-1,2,3-triazol-1-yl)phenethyl)piperidine
(RB-058). Compound RB-058 was prepared from 27 according to a
coupling procedure similar to that described for RB-057. Yield = 81%;
1H NMR (400 MHz, CDCl3) δ 0.91 (t, J = 6.9 Hz, 3H), 1.36−1.43 (m,
4H), 1.47−1.52 (m, 2H), 1.67−1.77 (m, 6H), 2.53−2.61 (m, 4H),
2.65−2.69 (m, 2H), 2.78 (d, J = 7.7 Hz, 2H), 2.92−2.96 (m, 2H), 7.34
(d, J = 8.4 Hz, 2H), 7.62 (d, J = 8.4 Hz, 2H), 7.69 (s, 1H); 13C NMR
(100 MHz, CDCl3) δ 14.0, 22.4, 24.0, 25.5, 25.7, 29.1, 31.5, 32.7, 54.4,
60.7, 118.8, 120.5, 129.9, 135.6, 140.6, 149.1; ESI-HRMS (M +H)+m/z
calcd for C20H31N4 327.2549, found 327.2543.
1-(4-(4-Octyl-1H-1,2,3-triazol-1-yl)phenethyl)piperidine (RB-
059). To a solution of RB-056 (50 mg, 0.17 mmol) and triethylamine
(116 μL, 0.83 mmol) in CH2Cl2 (5 mL) at 0 °C was added
methanesulfonyl chloride (39 μL, 0.51 mmol). After being stirred at
room temperature for 5 h, the reaction mixture was evaporated, diluted
with water, and the product was extracted with EtOAc. The extract was
washed with brine, dried, and evaporated to aﬀord 28 as a yellow liquid.
To a solution of 65mg (0.17mmol) of 28 (without puriﬁcation) in 3mL
of acetonitrile was added piperidine (168 μL, 1.70 mmol). The reaction
mixture was stirred at 50 °C for 12 h and concentrated. Puriﬁcation by
silica gel chromatography, eluting with CH2Cl2/MeOH (5:1), gave 11
mg (66%) of RB-059 as a slightly yellow waxy solid. 1H NMR (400
MHz, CDCl3) δ 0.88 (t, J = 6.8 Hz, 3H), 1.25−1.39 (m, 10H), 1.58−
1.62 (m, 2H), 1.72 (quin, J = 7.3 Hz, 2H), 1.89 (quin, J = 5.1 Hz, 4H),
2.78 (t, J = 7.7 Hz, 2H), 2.96−3.04 (m, 6H), 3.14−3.18 (m, 2H), 7.40
(d, J = 8.1 Hz, 2H), 7.64 (d, J = 8.1 Hz, 2H), 7.67 (s, 1H); 13C NMR
(100 MHz, CDCl3) δ 14.0, 22.6, 22.8, 23.9, 25.6, 29.1, 29.2, 29.3, 30.9,
31.8, 53.8, 59.1, 118.9, 120.6, 130.0, 135.8, 138.5, 149.1, 173.3; ESI-
HRMS (M + H)+ m/z calcd for C23H37N4 369.3013, found 369.3015;
(M + H−N2)+ m/z calcd for C23H35N2 341.2951, found 341.2954.
1-(4-(4-Butyl-1H-1,2,3-triazol-1-yl)phenethyl)-1-methylpi-
peridinium Methanesulfonate (RB-060). To a solution of 26 (15
mg, 46 μmol) in 3 mL of acetonitrile was added 1-methylpiperidine (23
mg, 0.23 mmol). The reaction mixture was stirred at 50 °C for 12 h and
concentrated. The residue was washed with hexane to give 16 mg (82%)
of RB-060 as a yellow oil. 1H NMR (400MHz, CDCl3) δ 0.95 (t, J = 7.3
Hz, 3H), 1.41 (sex, J = 7.5 Hz, 2H), 1.66−1.74 (m, 4H), 1.80−1.87 (m,
4H), 2.77 (s, 3H), 2.74−2.84 (m, 2H), 3.13−3.17 (m, 2H), 3.26 (s, 3H),
3.57 (t, J = 5.5 Hz, 4H), 3.71−3.76 (m, 2H), 7.54 (d, J = 8.5 Hz, 2H),
7.62 (d, J = 8.5 Hz, 2H), 7.76 (s, 1H); 13C NMR (100 MHz, CDCl3) δ
13.9, 20.2, 20.8, 21.5, 22.3, 22.8, 25.3, 27.8, 31.5, 39.6, 44.2, 55.4, 61.0,
119.1, 120.6, 120.7, 136.1, 136.2, 149.2; ESI-HRMS (M)+ m/z calcd for
C20H31N4
+ 327.2549, found 327.2546.
1-Methyl-1-(4-(4-pentyl-1H-1,2,3-triazol-1-yl)phenethyl)-
piperidinium Methanesulfonate (RB-061). Compound RB-061
was prepared from 27 according to a coupling procedure similar to that
described for RB-060. Yield = 77%; 1HNMR (400MHz, CDCl3) δ 0.90
(t, J = 7.2 Hz, 3H), 1.34−1.39 (m, 4H), 1.68−1.75 (m, 4H), 1.81−1.86
(m, 4H), 2.76 (s, 3H), 2.74−2.83 (m, 2H), 3.13−3.18 (m, 2H), 3.28 (s,
3H), 3.59 (t, J = 5.5 Hz, 4H), 3.75−3.79 (m, 2H), 7.55 (d, J = 8.5 Hz,
2H), 7.64 (d, J = 8.5 Hz, 2H), 7.76 (s, 1H); 13C NMR (100 MHz,
CDCl3) δ 14.0, 20.2, 20.8, 21.5, 22.4, 22.8, 25.6, 27.9, 29.1, 31.5, 39.7,
44.2, 55.3, 61.0, 119.0, 120.6, 120.8, 130.3, 130.8, 136.0, 136.2, 149.3;
ESI-HRMS (M)+ m/z calcd for C21H33N4
+ 341.2705, found 341.2704.
1-Methyl-1-(4-(4-octyl-1H-1,2,3-triazol-1-yl)phenethyl)-
piperidinium Methanesulfonate (RB-062). Compound RB-062
was prepared from 28 according to a coupling procedure similar to that
described for RB-060. Yield = 71%; 1HNMR (400MHz, CDCl3) δ 0.87
(t, J = 7.1 Hz, 3H), 1.27−1.49 (m, 10H), 1.71−1.78 (m, 4H), 1.85−1.89
(m, 4H), 2.76 (s, 3H), 2.80−2.90 (m, 2H), 3.14−3.18 (m, 2H), 3.35 (s,
3H), 3.48 (t, J = 5.5 Hz, 4H), 3.67−3.85 (m, 2H), 7.60 (d, J = 8.5 Hz,
2H), 7.68 (d, J = 8.5 Hz, 2H), 7.83 (s, 1H); 13C NMR (100 MHz,
CDCl3) δ 14.2, 20.2, 20.5, 20.9, 21.4, 22.7, 23.0, 25.7, 27.9, 28.9, 29.1,
29.3, 29.4, 29.5, 31.9, 39.6, 44.0, 55.0, 61.1, 119.1, 120.4, 120.8, 130.2,
130.8, 136.1, 136.3, 149.3; ESI-HRMS (M)+ m/z calcd for C24H39N4
+
383.3169, found 383.3174.
1-(4-(4-Butyl-1H-1,2,3-triazol-1-yl)phenethyl)piperidin-4-ol
(RB-063). Compound RB-063 was prepared from 26 according to a
coupling procedure similar to that described for RB-057, using 4-
hydroxypiperidine. Yield = 65%; 1H NMR (400MHz, CDCl3) δ 0.96 (t,
J = 7.4 Hz, 3H), 1.42 (sex, J = 7.4 Hz, 2H), 1.60−1.75 (m, 4H), 1.93−
1.97 (m, 2H), 2.26 (t, J = 9.4Hz, 2H), 2.60−2.65 (m, 2H), 2.79 (t, J = 7.7
Hz, 2H), 2.85−2.89 (m, 4H), 3.75 (sep, J = 4.4 Hz, 1H), 7.33 (d, J = 8.4
Hz, 2H), 7.62 (d, J = 8.4 Hz, 2H), 7.69 (s, 1H); 13C NMR (100 MHz,
CDCl3) δ 13.9, 22.3, 25.3, 29.7, 31.5, 33.3, 34.4, 51.1, 60.0, 67.6, 118.8,
120.4, 129.9, 135.5, 141.0, 149.1; ESI-HRMS (M + H)+ m/z calcd for
C19H29N4O 329.2341, found 329.2336.
1-(4-(4-Pentyl-1H-1,2,3-triazol-1-yl)phenethyl)piperidin-4-ol
(RB-064). Compound RB-064 was prepared from 27 according to a
coupling procedure similar to that described for RB-057, using 4-
hydroxypiperidine. Yield = 70%; 1H NMR (400MHz, CDCl3) δ 0.90 (t,
J = 7.1 Hz, 3H), 1.34−1.42 (m, 4H), 1.61−1.77 (m, 4H), 1.93−1.97 (m,
2H), 2.26 (t, J = 9.5 Hz, 2H), 2.61−2.65 (m, 2H), 2.78 (t, J = 7.7 Hz,
2H), 2.85−2.89 (m, 4H), 3.75 (sep, J = 4.2 Hz, 1H), 7.33 (d, J = 8.4 Hz,
2H), 7.62 (d, J = 8.4 Hz, 2H), 7.69 (s, 1H); 13C NMR (100 MHz,
CDCl3) δ 14.0, 22.4, 25.6, 29.1, 31.4, 33.3, 34.4, 51.0, 60.0, 67.6, 118.8,
120.4, 129.9, 135.5, 141.0, 149.1; ESI-HRMS (M + H)+ m/z calcd for
C20H31N4O 343.2498, found 343.2495.
1-(4-(4-Octyl-1H-1,2,3-triazol-1-yl)phenethyl)piperidin-4-
amine (RB-065). Compound RB-065 was prepared from 28 according
to a coupling procedure similar to that described for RB-057, using 4-
hydroxypiperidine. Yield = 63%; 1H NMR (400MHz, CDCl3) δ 0.87 (t,
J = 6.7 Hz, 3H), 1.27−1.39 (m, 12H), 1.71 (quin, J = 7.5 Hz, 2H), 1.77−
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1.84 (m, 2H), 2.10−2.15 (m, 2H), 2.77 (t, J = 7.7 Hz, 4H), 2.91−2.95
(m, 2H), 3.05−3.07 (m, 2H), 3.09−3.14 (m, 2H), 3.89−3.93 (m, 1H),
7.37 (d, J = 8.4 Hz, 2H), 7.63 (d, J = 8.4 Hz, 2H); 13C NMR (100 MHz,
CDCl3) δ 14.1, 22.6, 25.6, 29.1, 29.2, 29.3, 29.4, 31.7, 50.0, 58.9, 118.9,
120.6, 130.0, 135.8, 138.9, 149.2; ESI-HRMS (M + H)+ m/z calcd for
C23H37N4O 385.2962, found 385.2965.
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